CA2598350C - Enhanced efficacy aluminum or aluminum-zirconium antiperspirant salt compositions containing calcium salt(s) and betaine - Google Patents
Enhanced efficacy aluminum or aluminum-zirconium antiperspirant salt compositions containing calcium salt(s) and betaine Download PDFInfo
- Publication number
- CA2598350C CA2598350C CA2598350A CA2598350A CA2598350C CA 2598350 C CA2598350 C CA 2598350C CA 2598350 A CA2598350 A CA 2598350A CA 2598350 A CA2598350 A CA 2598350A CA 2598350 C CA2598350 C CA 2598350C
- Authority
- CA
- Canada
- Prior art keywords
- peak
- antiperspirant
- composition
- antiperspirant composition
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/28—Zirconium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/26—Aluminium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q15/00—Anti-perspirants or body deodorants
Abstract
An antiperspirant composition comprising an antiperspirant salt selected from an aluminum antiperspirant salt, an aluminum-zirconium antiperspirant salt, and a mixture thereof; a betaine component selected from betaine, betaine hydrochloride, and a mixture thereof; a calcium salt; and water.
Description
TITLE OF THE INVENTION
ENHANCED EFFICACY ALUMINUM OR ALUMINUM-ZIRCONIUM
ANTIPERSPIRANT SALT COMPOSITIONS CONTAINING CALCIUM SALT(S) AND
BETAINE
BACKGROUND OF THE INVENTION
[0001] The efficacy of an antiperspirant salt can be increased, improved and/or sustained for a longer period of time by enhancing the amount of small molecules of the antiperspirant active salt. Typically, when an aluminum or aluminum-zirconium antiperspirant salt is formed, it tends to polymerize into a number of polymeric species. Each polymeric species is correlated with at least one HPLC peak (also referred to as a GPC peak in United States Patent No. 6,066,314). In United States Patent No. 6,066,314, Figures 1-6 thereof represent GPC plots of peaks 1, 2, 3, 4, 5 and 6. Peak 1 corresponds to a zirconium polymeric species with peaks 2-6 corresponding to aluminum polymeric species.
The area under the curve (AUC) at the position of each peak is proportional to the amount of the corresponding polymeric species.
ENHANCED EFFICACY ALUMINUM OR ALUMINUM-ZIRCONIUM
ANTIPERSPIRANT SALT COMPOSITIONS CONTAINING CALCIUM SALT(S) AND
BETAINE
BACKGROUND OF THE INVENTION
[0001] The efficacy of an antiperspirant salt can be increased, improved and/or sustained for a longer period of time by enhancing the amount of small molecules of the antiperspirant active salt. Typically, when an aluminum or aluminum-zirconium antiperspirant salt is formed, it tends to polymerize into a number of polymeric species. Each polymeric species is correlated with at least one HPLC peak (also referred to as a GPC peak in United States Patent No. 6,066,314). In United States Patent No. 6,066,314, Figures 1-6 thereof represent GPC plots of peaks 1, 2, 3, 4, 5 and 6. Peak 1 corresponds to a zirconium polymeric species with peaks 2-6 corresponding to aluminum polymeric species.
The area under the curve (AUC) at the position of each peak is proportional to the amount of the corresponding polymeric species.
[0002] Without being bound by theory, it is believed that the size of the polymeric species corresponding to peaks 5 and 6 are smaller than the polymeric species corresponding to the other aluminum peaks (i.e., peaks 2-4). Again without being bound by theory, it is believed that the sequence of the peaks corresponds to the size of the corresponding aluminum polymerics so that peak 2 polymer size > peak 3 polymer size > peak 4 polymer size > peak 5 polymer size > peak 6 polymer size.
[0003] It is further believed, without being bound by theory, that the antiperspirant efficacy of a given antiperspirant is inversely proportional to the polymer size of the relevant polymeric species. Also without being bound by theory, this is believed to be true because smaller antiperspirant polymeric species can more readily occlude a pore to a degree sufficient to produce the desired antiperspirant effect. In sum, it is believed that smaller species plug-up the sweat pores more readily and more effectively than do the larger species and, therefore, antiperspirants having a higher proportion of the smaller species will be more effective.
[0004] This theory is the basis for the discussion of peak ratios described in United States Patent Nos. 6,066,314 published on May 25, 2000 (assigned to the Colgate-Palmolive Co.) and 6,245,325 published on June 12, 2001 (assigned to the Gillette Company). In the '325 patent, there is a discussion of the ratio of the peak 4 AUC/peak 3 AUC. This ratio can be increased by increasing the portion of the smaller peak 4 species and/or decreasing the relative portion of the larger peak 3 species. Thereby, the efficacy of the antiperspirant can be enhanced, increased and/or maintained for a longer period of time. In effect, the effort is to improve the stability of the smaller peak 4 species over that of the larger peak 1, 2, and/or 3 species.
[0004a] U.S. Patent No. 6,066,314 describes the use of GPC-ICP to investigate whether zirconium and aluminum species co-elute at similar retention times or elute separately from the column at different retention times. The ICP unit is directly coupled to the GPC unit as a detector so that the oligomeric fractions separated by the GPC column are elucidated on-line quantitatively for Al, Zr and other elements.
The ICP's detector is a simultaneous charge induction device (CID) with a wavelength of 175 to 800 nm. The eluent from the GPC column is analyzed and a data point is noted about once every six seconds for Al and Zr. The data points collected are plotted against retention time, to form the chromatogram for each element separately. The number for the individual peak areas represents the relative concentration for that specific element.
[0004b] U.S. Patent No. 6,066,314 also describes that the method of characterizing and monitoring the zirconium and aluminum content and species in an aqueous solution of zirconium and aluminum, especially ZAG solutions, may be done by combining GPC and ICP. This is useful to investigate whether zirconium and aluminum species co-elute at similar retention times or elute separately from the column at different retention times. In one method the GPC column separates the species by molecular size, using a refractive index (RI) detector connected to the column outlet. The eluent fractions from the GPC are evaluated further by analysis of the individual fractions by ICP. In a second method, GPC may be directly coupled to ICP. The eluent fractions passing through the column are directly linked to the ICP
unit; the ICP unit in this case is used as a detector. Data points are collected such la as, for example, one data point every 6 seconds. For either of these methods data may be plotted and the presence of small Zr species monitored.
[0004c] Finally, U.S. Patent No. 6,066,314 describes an analytical technique for monitoring Zr species of peak 1. A fifty two percent solution of a ZAG
salt (Reza) 36-G, Reheis Inc., Berkeley Heights, N.J.; Zr/glycine weight ratio approximately 1:1), is prepared in distilled water. This is done by adding 48.0 g of water to 52.0 g of the ZAG salt with stirring at room temperature for about 5 minutes. This solution is further diluted to a 10% solution (19.23 g of the 50% solution+80.77 g water) for GPC
analysis. The chromatogram is run using the following parameters: Waters 600 analytical pump and controller, Rheodyne 77251 injector, Protein-Pak 125 (Waters) column, Waters 410 Differential Refractometer detector, 5.56 mM nitric acid mobile phase, 0.70 ml/min flow rate, 2.0 microliter injection volume. Data was analyzed using Waters millenium 2.1 software (Waters Corporation, Milford, Mass.). In order to investigate whether zirconium and aluminum species co-elute at similar retention times or elute separately from the column at different retention times, GPC
was coupled to ICP (unit obtained from Thermal-Jarrel-Ash, Inc., Franklin, Mass.).
The ICP unit is connected to the GPC unit as a detector so that the oligomeric fractions separated by the GPC column is elucidated on-line quantitatively for Al, Zr and other elements. The eluent from the GPC column is analyzed once every 6 seconds for Al and Zr. The ICP's detector is a simultaneous charge induction device (CID) with a wavelength of 175 to 800 nm. The data points collected are plotted against retention time, to create a chromatogram for each element separately. 5 peaks are identified by their retention times (RT) as follows: peak 1 (Kd=O), peak 2 (Kd=0.05), peak 3 (Kd=0.20 ), peak 4 (Kd=0.33 ) and peak 5 & 6 (Kd=0.53). Peak 1 of the GPC
profile is identified as exclusively oligomeric and polymeric zirconium species, while peaks 3, 4, and 5, 6 are identified as aluminum species.
[0004d] As indicated above, peak 1 is generated from zirconium oligomers while peaks 3, 4, and "5,6" are from aluminum oligomers. Peaks 1 and 4 are generally correlated with antiperspirant activity; however, peak 1 has a greater correlation with clinical efficacy than peak 4. After 3 months of aging, peak 4 is approximately constant in area while peak 1 has almost doubled in area. The increase in peak 1 area is due to the formation of large oligomeric zirconium species.
lb Since the efficacy of Rezal 36-G is known to decrease with aging, this decrease in efficacy is believed to be primarily due to the formation of large oligomeric zirconium species.
[0004e] U.S. Patent No. 6,245,325 describes a standard procedure for obtaining chromatograms by HPLC analysis. Salt solutions are evaluated for aluminum polymer distribution by HPLC at a concentration of about 10% Al or AI-Zr salt. If the solution to be analyzed is at a higher salt concentration, it is diluted with sufficient water to bring the salt concentration to about 10%. A 1.0 pL sample is pumped through a 4.6 mm x 50 cm column packed with Nucleosil 100-5 (Keystone Scientific Inc.) using a 0.01 M aqueous nitric acid solution as the eluent.
The flow rate of the mobile phase was controlled at 0.5 mL/min with a Waters 100 unit. HPLC
profiles were recorded and processed with a computerized system that included the Millennium 2010 Chromatography Manager software from the Millipore/Waters Corp.
A Waters 410 differential refractometer was used as the refractive index detector.
The HPLC profiles are read from left to right (higher to lower molecular weight).
Following this technique, peaks 3 and 4 appear at retention times of Kd=0.32-0.38 and Kd=0.49-0.53 respectively. Naturally, of course, other HPLC techniques which use different column materials, eluents and flow rates can be used provided that they sufficiently resolve peaks 3 and 4 with an acceptable degree of precision (i.e. the technique must be capable of resolving the Al into five distinct peaks).
Obviously, such other techniques may place peaks 3 and 4 at different retention times from those given above.
1c [0005] To ascertain whether a particular antiperspirant's efficacy has been improved, a number of ingredients may be added to the antiperspirant and then the peak 4 AUC/peak 3 AUC ratio measured by HPLC or GPC as described in the `314 patent. So, as the peak 4 AUC/peak 3 AUC ratio is increased, the proportion of the desirable smaller peak 4 species is increased relative to the less desirable larger peak 3 species.
[0004a] U.S. Patent No. 6,066,314 describes the use of GPC-ICP to investigate whether zirconium and aluminum species co-elute at similar retention times or elute separately from the column at different retention times. The ICP unit is directly coupled to the GPC unit as a detector so that the oligomeric fractions separated by the GPC column are elucidated on-line quantitatively for Al, Zr and other elements.
The ICP's detector is a simultaneous charge induction device (CID) with a wavelength of 175 to 800 nm. The eluent from the GPC column is analyzed and a data point is noted about once every six seconds for Al and Zr. The data points collected are plotted against retention time, to form the chromatogram for each element separately. The number for the individual peak areas represents the relative concentration for that specific element.
[0004b] U.S. Patent No. 6,066,314 also describes that the method of characterizing and monitoring the zirconium and aluminum content and species in an aqueous solution of zirconium and aluminum, especially ZAG solutions, may be done by combining GPC and ICP. This is useful to investigate whether zirconium and aluminum species co-elute at similar retention times or elute separately from the column at different retention times. In one method the GPC column separates the species by molecular size, using a refractive index (RI) detector connected to the column outlet. The eluent fractions from the GPC are evaluated further by analysis of the individual fractions by ICP. In a second method, GPC may be directly coupled to ICP. The eluent fractions passing through the column are directly linked to the ICP
unit; the ICP unit in this case is used as a detector. Data points are collected such la as, for example, one data point every 6 seconds. For either of these methods data may be plotted and the presence of small Zr species monitored.
[0004c] Finally, U.S. Patent No. 6,066,314 describes an analytical technique for monitoring Zr species of peak 1. A fifty two percent solution of a ZAG
salt (Reza) 36-G, Reheis Inc., Berkeley Heights, N.J.; Zr/glycine weight ratio approximately 1:1), is prepared in distilled water. This is done by adding 48.0 g of water to 52.0 g of the ZAG salt with stirring at room temperature for about 5 minutes. This solution is further diluted to a 10% solution (19.23 g of the 50% solution+80.77 g water) for GPC
analysis. The chromatogram is run using the following parameters: Waters 600 analytical pump and controller, Rheodyne 77251 injector, Protein-Pak 125 (Waters) column, Waters 410 Differential Refractometer detector, 5.56 mM nitric acid mobile phase, 0.70 ml/min flow rate, 2.0 microliter injection volume. Data was analyzed using Waters millenium 2.1 software (Waters Corporation, Milford, Mass.). In order to investigate whether zirconium and aluminum species co-elute at similar retention times or elute separately from the column at different retention times, GPC
was coupled to ICP (unit obtained from Thermal-Jarrel-Ash, Inc., Franklin, Mass.).
The ICP unit is connected to the GPC unit as a detector so that the oligomeric fractions separated by the GPC column is elucidated on-line quantitatively for Al, Zr and other elements. The eluent from the GPC column is analyzed once every 6 seconds for Al and Zr. The ICP's detector is a simultaneous charge induction device (CID) with a wavelength of 175 to 800 nm. The data points collected are plotted against retention time, to create a chromatogram for each element separately. 5 peaks are identified by their retention times (RT) as follows: peak 1 (Kd=O), peak 2 (Kd=0.05), peak 3 (Kd=0.20 ), peak 4 (Kd=0.33 ) and peak 5 & 6 (Kd=0.53). Peak 1 of the GPC
profile is identified as exclusively oligomeric and polymeric zirconium species, while peaks 3, 4, and 5, 6 are identified as aluminum species.
[0004d] As indicated above, peak 1 is generated from zirconium oligomers while peaks 3, 4, and "5,6" are from aluminum oligomers. Peaks 1 and 4 are generally correlated with antiperspirant activity; however, peak 1 has a greater correlation with clinical efficacy than peak 4. After 3 months of aging, peak 4 is approximately constant in area while peak 1 has almost doubled in area. The increase in peak 1 area is due to the formation of large oligomeric zirconium species.
lb Since the efficacy of Rezal 36-G is known to decrease with aging, this decrease in efficacy is believed to be primarily due to the formation of large oligomeric zirconium species.
[0004e] U.S. Patent No. 6,245,325 describes a standard procedure for obtaining chromatograms by HPLC analysis. Salt solutions are evaluated for aluminum polymer distribution by HPLC at a concentration of about 10% Al or AI-Zr salt. If the solution to be analyzed is at a higher salt concentration, it is diluted with sufficient water to bring the salt concentration to about 10%. A 1.0 pL sample is pumped through a 4.6 mm x 50 cm column packed with Nucleosil 100-5 (Keystone Scientific Inc.) using a 0.01 M aqueous nitric acid solution as the eluent.
The flow rate of the mobile phase was controlled at 0.5 mL/min with a Waters 100 unit. HPLC
profiles were recorded and processed with a computerized system that included the Millennium 2010 Chromatography Manager software from the Millipore/Waters Corp.
A Waters 410 differential refractometer was used as the refractive index detector.
The HPLC profiles are read from left to right (higher to lower molecular weight).
Following this technique, peaks 3 and 4 appear at retention times of Kd=0.32-0.38 and Kd=0.49-0.53 respectively. Naturally, of course, other HPLC techniques which use different column materials, eluents and flow rates can be used provided that they sufficiently resolve peaks 3 and 4 with an acceptable degree of precision (i.e. the technique must be capable of resolving the Al into five distinct peaks).
Obviously, such other techniques may place peaks 3 and 4 at different retention times from those given above.
1c [0005] To ascertain whether a particular antiperspirant's efficacy has been improved, a number of ingredients may be added to the antiperspirant and then the peak 4 AUC/peak 3 AUC ratio measured by HPLC or GPC as described in the `314 patent. So, as the peak 4 AUC/peak 3 AUC ratio is increased, the proportion of the desirable smaller peak 4 species is increased relative to the less desirable larger peak 3 species.
[0006] This peak 4 AUC/peak 3 AUC ratio is also referred to herein as the peak 4/peak 3 ratio or a "first ratio." Another peak ratio, i.e., the peak 1 AUC/( peak 2 AUC +
peak 3 AUC + peak 4 AUC + peak 5 AUC + peak 6 AUC) ratio is referred to herein as the "second ratio." Also, because peaks 5 and 6 often appear as a single merged peak at peak 5, this "second ratio" is also sometimes referred to as the peak 1 AUC/( peak 2 AUC + peak 3 AUC + peak 4 AUC + peak 5 AUC) ratio with the understanding that the peak 6 AUC is part of the peak 5 AUC.
peak 3 AUC + peak 4 AUC + peak 5 AUC + peak 6 AUC) ratio is referred to herein as the "second ratio." Also, because peaks 5 and 6 often appear as a single merged peak at peak 5, this "second ratio" is also sometimes referred to as the peak 1 AUC/( peak 2 AUC + peak 3 AUC + peak 4 AUC + peak 5 AUC) ratio with the understanding that the peak 6 AUC is part of the peak 5 AUC.
[0007] Additionally, the "first ratio" is proportional to an 27a1 NMR peak appearing at 63.5ppm. Thus, an increase in the "first ratio" and an increase in the intensity of the "27a1 NMR peak appearing at 63.5ppm", each represent what is believed to be an increase in the amount of the peak 4 species relative to the amounts of the other polymeric species of the other 2, 3, 5 and 6 peaks. It should be born in mind that peak 1 corresponds to zirconium species and peaks 2-6 correspond to aluminum species.
[0008] While the above-noted theory is believed to be sound, such understanding is made without being bound by theory in the event that the changes measured in the "first ratio", "second ratio" and the "27a1 NMR peak appearing at 63.5ppm" yield a more efficacious antiperspirant product due to some, as yet, unrecognized mechanism.
[0009] With the foregoing background being provided, there is a need to provide a more effective antiperspirant product. It is believed that a more effective antiperspirant product can be provided by increasing its "first ratio," decreasing its "second ratio," and/or increasing the intensity of the "27a1 NMR peak appearing at 63.5ppm."
[00101 It is desirable to provide a more effective antiperspirant. It is also desirable to provide an antiperspirant with an increased "first ratio" and/or a decreased "second ratio." It is also desirable to provide an antiperspirant having an increased intensity of the "27a1 NMR
peak appearing at 63.5ppm."
SUMMARY OF THE INVENTION
[0011] An improved or more effective antiperspirant composition is provided in accordance with one embodiment of the invention. According to one embodiment, the more effective antiperspirant composition comprises:
(a) an antiperspirant salt selected from the group consisting of an aluminum antiperspirant salt, an aluminum-zirconium antiperspirant salt, and a mixture thereof;
(b) a betaine component selected from the group consisting of betaine, betaine hydrochloride, and a mixture thereof; and (c) a calcium salt .
Other embodiments within the scope of the present invention are also contemplated as discussed and illustrated below.
DETAILED DESCRIPTION OF EMBODIMENT(S) OF THE INVENTION
[0012] At the outset, it should be noted that this application discusses various embodiment(s) and examples in accordance with the present invention. No part of this application is intended to be construed to limit the scope of the claimed invention whether in the Background of the Invention, the Summary of the Invention, the Examples or in the Detailed Description of Embodiment(s) of the Invention. All discussions in this application are to be construed as illustrative, exemplary and non-limiting with regard to the scope of the claimed invention.
[0013] Unless expressly indicated otherwise, amount(s) of each ingredient noted in this application are provided in "% by weight" units based on the total amount of the entire antiperspirant composition recited in the claim(s).
[0014] One exemplary embodiment of the invention is the antiperspirant composition noted above in the Summary of the Invention. Each component is now discussed in order below.
[0015] Suitable examples of aluminum salts, aluminum/zirconium salts or mixtures thereof for use in connection with the claimed invention include, but are not limited to, conventional aluminum and aluminum/zirconium salts, as well as aluminum/zirconium salts complexed with a complexing agent, such as glycols, as are known in the art in the form of aluminum zirconium chiorohydrex propylene glycol complex, aluminum zirconium chlorohydrex dipropylene glycol complex, aluminum zirconium chlorohydrex tripropylene glycol complex and mixtures of any of the foregoing.
[00161 Suitable examples of zirconium salts for use in connection with the claimed invention include (but are not limited to) zirconyl hydroxychlorides, zirconyl oxychlorides, basic aluminum chlorides combined with zirconyl oxychlorides and hydroxychlorides, and organic complexes of each of basic aluminum chlorides with zirconyl oxychlorides and hydroxychlorides and mixtures of any of the foregoing. Generally, the foregoing metal antiperspirant active materials are antiperspirant active metal salts.
[0017] Suitable aluminum salts for use in conjunction with the claimed invention include, but are not limited to, aluminum chlorohydrate, aluminum dichlorohydrate, aluminum sesquichlorohydrate, aluminum chlorohydrex propylene glycol, aluminum dichlorohydrex propylene glycol, aluminum sesquichlorohydrex propylene glycol, aluminum chlorohydrex polyethylene glycol, aluminum dichlorohydrex polyethylene glycol, aluminum sesquichlorohydrex polyethylene glycol and combinations thereof. See also the `314 and `325 patents and references cited therein..
[0018] Exemplary suitable amounts of the component (a) antiperspirant used in conjunction with the claimed invention include, but are not limited to, (1) from about 5 to about 85% (or from 5-85%), (2) from about 5 to about 78% (or from 5-78%), (3) from about to about 70% (or from 10-70 /a), (4) from about 10 to about 60% (or from 10-60%), (5) from about 12 to about 50% (or from 12-50%), (6) from about 13 to about 40%
(or from 13-40%), and (7) from about 15 to about 35% (or from 15-35%).
[0019] It should be noted that whatever the amount of the component (a) antiperspirant, the total amount of the final claimed antiperspirant composition (including any optional or other ingredients) cannot exceed 100%.
[0020] The "betaine" recited in the claims means the "betaine" of Formula I:
CH3 C=0 I(+) ~
H3C- i -CH2 CH3 (Formula I).
In IUPAC nomenclature, betaine is 1-carboxy-N,N,N-trimethylmethanaminium hydroxide-inner salt, with alternative names including carboxymethyl-trimethyl-ammonium betaine or (carboxymethyl)trimethylammonium hydroxide-inner salt or glycine betaine or glycol betaine or glycyl betaine or trimethylglycine or trimethylglycol. For convenience here the material of Formula I (C5H11N02 ; Mass = 117.08 ainu; molecular weight =
117.15;
analysis as C: 51.26; H: 9.46; N: 11.96; 0: 27.32) will be referred to herein as "betaine."
[0021] While betaine is sometimes incorrectly referred to as an amino acid, it is in fact a zwitterion. For purposes of this application, betaine is not considered to be an amino acid. The betaine used in this invention is a natural product found in a number of plants in the Chenopodiaceae family, and also in fish and selected, legumes. Its synthetic analog can also be used. It is extracted most often from sugar beets (Beta Vulgaris).
[0022] Exemplary suitable amounts of the component (b) betaine used in conjunction with the claimed invention include, but are not limited to, (1) at least about 0.1% (or >_0.1%), (2) from about 0.5 to about 40% (or from 0.5-40%), (3) from about 1.0 to about 35% (or from 1.0-35%), (4) from about 2.0 to about 30% (or from 2.0-30%), (5) from about 3.0 to about 25% (or from 3.0-25%), (6) from about 4.0 to about 20% (or from 4.0-20%), and (7) from about 4.5 to about 15% (or from 4.0-15%), and (7) from about 15 to about 35% (or from 15-35%).
[0023] It should be noted that whatever the amount of the component (b) betaine, the total amount of the final claimed antiperspirant composition (including any optional or other ingredients) cannot exceed 100%.
[0024] Suitable examples of Ca salts for use in connection with the claimed invention include, but are not limited to, calcium chloride, calcium bromide, calcium nitrate, calcium citrate, calcium formate, calcium acetate, calcium gluconate, calcium ascorbate, calcium lactate, calcium glycinate, calcium carbonate, calcium sulfate, calcium hydroxide or mixtures thereof.
[0025] Exemplary suitable amounts of the component (c) calcium salt used in conjunction with the claimed invention include, but are not limited to, (1) at least about 0.1%
(or >_0.1 %), (2) from about 0.2 to about 80% (or from 0.2-80%), (3) from about 0.3 to about 60% (or from 0.3-60%), (4) from about 0.4 to about 40% (or from 0.4-40%), (5) from about 0.45 to about 20% (or from 0.45-20%), and (6) from about 0.5 to about 10% (or from 0.5-10%).
[0026] It should be noted that whatever the amount of the component (c) calcium salt, the total amount of the final claimed antiperspirant composition (including any optional or other ingredients) cannot exceed 100%.
[0027] After any optional ingredients in the claimed antiperspirant composition of the claimed invention, water comprises the remainder thereof. It should be noted that whatever the amount of all the ingredients of the claimed composition including water (or any optional ingredients), the total amount of the final claimed antiperspirant composition cannot exceed 100%. In fact, the total of all the ingredients of the claimed composition (including any optional ingredients present) must total to 100%.
[0028] An exemplary optional component of the claimed antiperspirant composition may be one or more water soluble alcohol(s). Suitable examples of water soluble alcohol(s) for use with the claimed invention include, but are not limited to, C2-C8 alcohols, C2-C3 alcohols, ethanol, glycol (G), propylene glycol (PG), dipropylene glycol (DG), tripropylene glycol (TG) or mixtures thereof.
[0029] Exemplary suitable amounts of the optional water soluble alcohol used in conjunction with the claimed invention include, but are not limited to, (1) from about 0 to about 40% (or 0-40%), (2) from about 2 to about 35% (or from 2-35%), (3) from about 4 to about 30% (or from 4-30%), (4) from about 6 to about 25% (or from 6-25%), (5) from about 8 to about 20% (or from 8-20%), and (6) from about 10 to about 15% (or from 10-15%).
[0030] Optionally, glycine may be included in the claimed antiperspirant composition. Exemplary suitable amounts of the optional glycine used in conjunction with the claimed invention include, but are not limited to, (1) from about 0 to about 40% (or 0-40%), (2) from about 1 to about 30% (or from 1-30%), (3) from about 2 to about 20% (or from 2-2%), and (4) from about 4 to about 50% (or from 4-50%), (5) from about 6 to about 20% (or from 6-20%), and (6) from about 8 to about 10% (or from 8-10%).
[0031] Other optional ingredients such as fragrance(s), color(s), dye(s), pigment, etc.
maybe included in the claimed antiperspirant composition. See Handbook of Cosmetic Science and Technology, Editors - A. Bard, M. Paye and H. Maibach, Marcel Dekker, Inc., New York (2001); Antiperspirants and Deodorants, Editors - K. Laden and C.
Pelger, Cosmetic Science and Technology Series/Volume 7, Marcel Dekker, Inc., New York (1988);
and Antiperspirants and Deodorants, 2nd Edition, Editor - K Laden, Cosmetic Science and Technology Series/Volume 20, Marcel Dekker, Inc., New York (1999).
[0032] The claimed antiperspirant composition may be provided in various forms including, but not limited to, aerosol, gels, creams, solid stick, semi-solid stick, powder, liquid, emulsion, suspension, dispersion and the like. Preferably, the form is either a stick, semi-solid stick, liquid or powder. More preferably the form is either a liquid or a powder.
[0033] Also, the particular form of the claimed antiperspirant composition is preferably provided in a suitable container such as an aerosol can (aerosol), tube or container with porous cap (gel), roll-on or bottle (liquid), container with open end (stick, pad or wipe) and the like - whatever is suitable for the particular exemplary form. Of course, the claimed invention is claimed as the composition itself and does not require that it be dispensed or provided in a suitable container to fall within the scope of the appended claims.
[0034] Given the exemplary amounts of the foregoing components listed, it should be noted that the combination of the ingredients of the claimed antiperspirant composition should be sufficient to increase the "first ratio" by at least about (1) 0.5, (2) 0.8, (3) 1, (4) 1.5, (5) 2, (6) 2.5, (7) 3, (8) 3.5, (9) 4, or (10) 4.5, respectively, when compared to that of a comparable composition without both the betaine and calcium salt components.
Likewise, it is desired that the ingredients of the claimed antiperspirant composition should be sufficient to increase the "first ratio" (11) from about 0.5 to about 10, (12) from about 0.8 to about 8, (13) from about 1 to about 6, or (14) from about 1 to about 4, respectively, when compared to that of a comparable composition without both the betaine and calcium salt components.
[0035] Given the exemplary amounts of the foregoing components listed, it should be noted that the combination of the ingredients of the claimed antiperspirant composition should be sufficient to decrease the "second ratio" to less than about (1) 0.4, (2) 0.35, (3) 0.3, (4) 0.25, (5) 0.2, (6) 0.15, (7) 0.1, (8) 0.05, (9) 0.04, (10) 0.03, (11) 0.02, or (12), 0.01, respectively, when compared to that of a comparable composition without both the betaine and calcium salt components. Preferably, according to one embodiment, the claimed antiperspirant has a "second ratio" of 0.
[0036] Given the exemplary amounts of the foregoing components listed, it should be noted that the combination of the ingredients of the claimed antiperspirant composition should be sufficient to increase the "27A1 NMR peak intensity at 63.5ppm" by at least about (1) 20% (note peak intensity is not weight %), (2) 100%, (3) 200%, (4) 300%, (5) 400%, (6) 00%, (7) 600%, (8) 700%, (9) 800, or (10) 900, respectively, when compared to that of a comparable composition without both the betaine and calcium salt components.
Additional Examples Analytical Method for Examples a. Size exclusion chromatography ("SEC"):
(0037] Size exclusion chromatography ("SEC") or gel permeation chromatography ("GPC") are methods frequently used for obtaining information on polymer distribution in antiperspirant salt solutions. With appropriate chromatographic columns, at least five distinctive groups of polymer species can be detected in a ZAG, appearing in a chromatogram as peaks 1, 2, 3, 4 and a peak known as "5,6". Peak 1 is the larger zirconium species (greater than 60 Angstroms). Peaks 2 and 3 are larger aluminum species. Peak 4 is the smaller aluminum species (aluminum oligomers) and has been correlated with enhanced efficacy for both ACH and ZAG salts. Peak 5,6 is the smallest aluminum species. The relative retention time ("Kd") for each of these peaks varies depending on the experimental conditions. This method is also applicable to ZAB (zirconium-aluminum-betaine) salts. Data for Table A was obtained using the SEC method described in an issued patent owned by the same company as a this case, U.S. Patent 6,066,314.
b. NMR measnrements:Sample preparation:
[00381 Samples were prepared by diluting 0.2m1 product in 0.8m1 D20 to yield solution at concentrations of 7.0%. Samples were weighted and dissolved in D20 to produce 7.0% active solutions. A blank sample, using same type of NMR tube and only contain D20, was also prepared to obtained the background signal from the NMR probe and test tubes. All NMR measurements were preformed immediately after the samples were prepared.
c. NMR experimental conditions:
10039] Bruker Avance DMX500 NMR spectrometer with a inverse broadband 5 mm probe was used for all NMR measurements, which operated at the frequency of 130.323 MHz for 27A1. Single pulse with CYCLOPS was used during all experiments with recycle delay at 3 second, RF pulse width at 17 O s at 0 db RF attenuation (which is 90 degree pulse).
Total number of scans for each data set is 1024, and the 64K data points (correspond to 1 second acquisition time) were acquired for each FID data set. The spectral width is 32679 Hz, which is equivalent to 250 ppm. The dewell time is 20 Os, which is the delay time between the end of RF pulse and the starting point of data acquisition. The magnetic field was locked by deuteratied water in all the samples. All NMR experiments were carried out at room temperature (21 C) without specific temperature control. A blank NMR
spectrum of the background was also recorded with exactly the same parameters.
d. NMR data analysis:
[0040] All NMR F1D data were processed with same parameters: FFT data size was 64K, and an exponential window function (LB=5 Hz) was applied before FFT to improve signal to noise ratio. Since the blank spectrum showed a broad background 27A1 signal at 72 ppm, it were subtracted from all spectra for real samples to produce spectra without background signal. The subtractions were performed in spectral domain, where the exact same processing parameters were used for sample data set and the background signal, especially the phase parameters. Automatic baseline corrections were also performed on all data sets after background correction. Since there were severe signal overlap from -20 to 40 ppm, line shape deconvolutions were performed on all data sets to obtain peak position, line width, and integration. Initial conditions were set with four resonance signals in this region, usually several runs at different initial conditions were necessary to obtain good T
deconvolution results. The deconvolution function in Bruker X-WinNMR (version 2.5) was used, and a mixed line shape of Lorentzian and Gaussian (low percentage) was used for all data sets.
Antiperspirant Salts with Betaine and Calcium Example 1 [0041] A solution was made by mixing 4 gm of CaC12 and 2 gm of betaine anhydrous with 20 gm (USP weight) ACH powder (Reheis CHLORHYDROL ) in water, mating the total weight 100 gm. The solution was then divided into two parts:
One part was aged at 70 oC overnight, and the second part was kept at room temperature for the same time period. The sample solutions were analyzed afterwards by the SEC method described earlier, as well as the ACH solution as control. As shown in Table 1, after being aged, the ACH
sample with CaC12 and betaine showed significant increase in Peak-4/Peak-3 ratio, especially at higher temperature.
Table 1, SEC peak distribution (RI Detector) Sample Peak-4/Peak-3 ACH (20%, USP) 0.244 ACH (20%, USP) + CaC12 (4%) + betaine (2%) 1.43 (Aged at 70 C, overnight) ACH (20%, USP) + CaCIZ (4%) + betaine (2%) 0.65 (Aged at RT, overnight) NMR analysis also indicated that the peak-4 species created by mixing ACH, CaC12, and betaine was very close to that in Reach-101, a thennally activated ACH with Al 13-mers in peak-4. The strength of NMR peak at 63.5 ppm representing the Al tetrahedron in the center of Al 13-mer increased from 0.388 to 1.0854 after the regular ACH was mixed with CaCl2 and betaine and then aged, suggesting the enhancement of Al 13-mers by this process.
Table 2. Relative peak strength of 27A1 NMR
Sample 63.5 ppm ACH 0.388 Activated ACH, Reach-101 1.000 ACH (20%, USP) + CaC12 (4%) + betaine (2%) 1.085 (Aged at 70 C, overnight) Example 2 [0042] A solution was made by mixing 5 gm of CaC12 and 2 gm of betaine anhydrous with 20 gm (USP weight) ACH powder (Reheis CHL RHYDROL ) in water, making the total weight of 100 gm. The solution was aged at room temperature, and then analyzed at different periods of time by the SEC method described earlier, with the ACH
sample solution as control. As shown in Table 2, Peak-4 kept going up over time indicated by the increasing Peak-4/Peak-3 ratio.
Table 2, SEC peak distribution (RI Detector) Sample Peak-4/Peak-3 ACH (20%, USP) 0.24 ACH (20%, USP) + CaC12 (5%) + betaine (2%) 1.49 (Aged at RT, 1 week) ACH (20%, USP) + CaCl2 (5%) + betaine (2%) 1.72 (Aged at RT, 1 months) ACH (20%, USP) + CaC12 (5%) + betaine (2%) 2.35 (Aged at RT, 2 months) ACH (20%, USP) + CaCl2 (5%) + betaine (2%) 3.09 (Aged at RT, 6 months) Example 3 [0043] Different amount of CaC12 and betaine anhydrous were added into AZP-955 solution, a glycine free AI-Zr-chlorohydrex made by Reheis, Inc., to form four sample solutions with concentrations of the ingredients shown in Table 3. The sample solutions were aged at 45 oC a week afterwards, and then checked by SEC for polymer size distribution profile. Table 3 exhibits the peak ratios of peak-l/(peak-2 + peak-3 + peak-4 + peak-5) and Peak-4/peak-3, measuring large zirconium polymer species and aluminum 13-mers, or peak-4 species, respectively.
[0044] Obviously, both betaine and Ca++ ions were needed to boost peak-4 species, or aluminum 13-mers, in the sample solutions: The samples with both showed considerable increase in peak-4/peak-3 ratio, while the one with only betaine or CaC12 did not have any positive change in the ratio after being aged. Furthermore, dose response effect of CaC12 was clearly demonstrated in this example: The sample with higher level of Ca++
(6.54% of CaC12) presented a much higher peak-4/peak-3 ratio than the one with lower level of Ca++
(2.17% CaC12).
[0045] The effect of betaine in stabilizing zirconium species was also demonstrated in this example: All the sample solutions with the presence of betaine showed detectable reduction in peak-1/(peak-2 + peak-3 + peak-4 + peak-5) ratio, indicating small zirconium species being stabilized.
Table 3, SEC peak distribution (RI Detector) Sample Peak-1/(P2+P3+P4+P5) Peak-4/Peak-3 AZP-955 (18.9%) as control 0.38 0.29 AZP-955 (18.9%) + CaC12 (2.17%) + 0.26 0.85 betaine (3.3%) AZP-955 (18.9%) + CaC12 (6.54%) + 0.27 1.55 betaine (3.3%) AZP-955 (18.9%) + CaC12 (0%) + 0.23 0.25 betaine (3.3%) AZP-955 (18.9%) + CaC12 (2.17%) + 0.43 0.28 betaine (0%) Example 4 [0046] Samples were made by adding CaC12 and water into ZAB-317321-I, or ZAB-317321-II aqueous solution, the Reheis prepared Zr-Al-Chlorohydrex-betaine AP
salt with betaine/zirconium molar ratio of 0.82, or 1.32 respectively, to come out with the solution samples with concentration of ingredients listed in table 4. The samples were then aged for a month at room temperature.
[0047] Table 4 presents the SEC results in peak ratios of peak-1/(peak-2 +
peak-3 +
peak-4 + peak-5) and Peak-4/peak-3, clearly revealing the effect of combination of betaine and Ca++ on zirconium polymers and peak-4 species respectively. The samples with higher betaine level, betaine/zirconium of 1.23, exhibited lower peak ratios of peak-1/(peak-2 +
peak-3 + peak-4 + peak-5), suggesting more stabilized small zirconium species.
[0048] The trend was equally evident with regard to peak-4 species: The sample with the highest level of both Ca++ and betaine, 6.54% of CaC12 and betaine/zirconium ratio of 1.23, showed the highest peak-4/peak-3 ratio of 1.73, whereas the ones of lower levels of betaine and zirconium revealed lower peak-4/peak-3 ratios accordingly.
[0049] In addition, this example further proved that if without Ca++, betaine alone would not boost peak-4 species. The two samples with different level of betaine, while without Ca++, exhibited identical peak-4/peak-3 ratios.
Table 4, SEC peak distribution (RI Detector) Sample Peak-1/(P2+P3+P4+P5) Peak-4/Peak-ZAB-317321-I 0.17 0.27 (betaine/Zr=0.82) --19% solution ZAB-317321-I 0.17 0.57 (betaine/Zr=0.82) --19% solution +CaC12(2.17%) ZAB-317321-I 0.17 0.75 (betaine/Zr=0.82) --19% solution + CaC12 (6.54 %) ZAB-317321-II 0.03 0.27 (betaine/Zr=1.23) --19% solution ZAB-317321-II 0.03 0.94 (betaine/Zr=1.23) --19% solution + CaC12 (2.17 %) ZAB-317321-II 0.03 1.73 (betaine/Zr=1.23) --19% solution +CaC12(6.54%) Example 5 [0050] Dissolve 19.26 gm ZrOC12.8H20 and 8.39g betaine anhydrous in 30 gm of water to prepare an antiperspirant (AP) salt solution. After everything is dissolved, add ACH
powder (22.65 g of Chlorhydrol from Reheis Chemical Co., Berkeley Heights, NJ) and 12 gm of CaCl2.2H20 into the solution with additional water so that the total weight of the solution reaches 100 gm. Shake and/or stir the solution until the solution becomes clear.
[00101 It is desirable to provide a more effective antiperspirant. It is also desirable to provide an antiperspirant with an increased "first ratio" and/or a decreased "second ratio." It is also desirable to provide an antiperspirant having an increased intensity of the "27a1 NMR
peak appearing at 63.5ppm."
SUMMARY OF THE INVENTION
[0011] An improved or more effective antiperspirant composition is provided in accordance with one embodiment of the invention. According to one embodiment, the more effective antiperspirant composition comprises:
(a) an antiperspirant salt selected from the group consisting of an aluminum antiperspirant salt, an aluminum-zirconium antiperspirant salt, and a mixture thereof;
(b) a betaine component selected from the group consisting of betaine, betaine hydrochloride, and a mixture thereof; and (c) a calcium salt .
Other embodiments within the scope of the present invention are also contemplated as discussed and illustrated below.
DETAILED DESCRIPTION OF EMBODIMENT(S) OF THE INVENTION
[0012] At the outset, it should be noted that this application discusses various embodiment(s) and examples in accordance with the present invention. No part of this application is intended to be construed to limit the scope of the claimed invention whether in the Background of the Invention, the Summary of the Invention, the Examples or in the Detailed Description of Embodiment(s) of the Invention. All discussions in this application are to be construed as illustrative, exemplary and non-limiting with regard to the scope of the claimed invention.
[0013] Unless expressly indicated otherwise, amount(s) of each ingredient noted in this application are provided in "% by weight" units based on the total amount of the entire antiperspirant composition recited in the claim(s).
[0014] One exemplary embodiment of the invention is the antiperspirant composition noted above in the Summary of the Invention. Each component is now discussed in order below.
[0015] Suitable examples of aluminum salts, aluminum/zirconium salts or mixtures thereof for use in connection with the claimed invention include, but are not limited to, conventional aluminum and aluminum/zirconium salts, as well as aluminum/zirconium salts complexed with a complexing agent, such as glycols, as are known in the art in the form of aluminum zirconium chiorohydrex propylene glycol complex, aluminum zirconium chlorohydrex dipropylene glycol complex, aluminum zirconium chlorohydrex tripropylene glycol complex and mixtures of any of the foregoing.
[00161 Suitable examples of zirconium salts for use in connection with the claimed invention include (but are not limited to) zirconyl hydroxychlorides, zirconyl oxychlorides, basic aluminum chlorides combined with zirconyl oxychlorides and hydroxychlorides, and organic complexes of each of basic aluminum chlorides with zirconyl oxychlorides and hydroxychlorides and mixtures of any of the foregoing. Generally, the foregoing metal antiperspirant active materials are antiperspirant active metal salts.
[0017] Suitable aluminum salts for use in conjunction with the claimed invention include, but are not limited to, aluminum chlorohydrate, aluminum dichlorohydrate, aluminum sesquichlorohydrate, aluminum chlorohydrex propylene glycol, aluminum dichlorohydrex propylene glycol, aluminum sesquichlorohydrex propylene glycol, aluminum chlorohydrex polyethylene glycol, aluminum dichlorohydrex polyethylene glycol, aluminum sesquichlorohydrex polyethylene glycol and combinations thereof. See also the `314 and `325 patents and references cited therein..
[0018] Exemplary suitable amounts of the component (a) antiperspirant used in conjunction with the claimed invention include, but are not limited to, (1) from about 5 to about 85% (or from 5-85%), (2) from about 5 to about 78% (or from 5-78%), (3) from about to about 70% (or from 10-70 /a), (4) from about 10 to about 60% (or from 10-60%), (5) from about 12 to about 50% (or from 12-50%), (6) from about 13 to about 40%
(or from 13-40%), and (7) from about 15 to about 35% (or from 15-35%).
[0019] It should be noted that whatever the amount of the component (a) antiperspirant, the total amount of the final claimed antiperspirant composition (including any optional or other ingredients) cannot exceed 100%.
[0020] The "betaine" recited in the claims means the "betaine" of Formula I:
CH3 C=0 I(+) ~
H3C- i -CH2 CH3 (Formula I).
In IUPAC nomenclature, betaine is 1-carboxy-N,N,N-trimethylmethanaminium hydroxide-inner salt, with alternative names including carboxymethyl-trimethyl-ammonium betaine or (carboxymethyl)trimethylammonium hydroxide-inner salt or glycine betaine or glycol betaine or glycyl betaine or trimethylglycine or trimethylglycol. For convenience here the material of Formula I (C5H11N02 ; Mass = 117.08 ainu; molecular weight =
117.15;
analysis as C: 51.26; H: 9.46; N: 11.96; 0: 27.32) will be referred to herein as "betaine."
[0021] While betaine is sometimes incorrectly referred to as an amino acid, it is in fact a zwitterion. For purposes of this application, betaine is not considered to be an amino acid. The betaine used in this invention is a natural product found in a number of plants in the Chenopodiaceae family, and also in fish and selected, legumes. Its synthetic analog can also be used. It is extracted most often from sugar beets (Beta Vulgaris).
[0022] Exemplary suitable amounts of the component (b) betaine used in conjunction with the claimed invention include, but are not limited to, (1) at least about 0.1% (or >_0.1%), (2) from about 0.5 to about 40% (or from 0.5-40%), (3) from about 1.0 to about 35% (or from 1.0-35%), (4) from about 2.0 to about 30% (or from 2.0-30%), (5) from about 3.0 to about 25% (or from 3.0-25%), (6) from about 4.0 to about 20% (or from 4.0-20%), and (7) from about 4.5 to about 15% (or from 4.0-15%), and (7) from about 15 to about 35% (or from 15-35%).
[0023] It should be noted that whatever the amount of the component (b) betaine, the total amount of the final claimed antiperspirant composition (including any optional or other ingredients) cannot exceed 100%.
[0024] Suitable examples of Ca salts for use in connection with the claimed invention include, but are not limited to, calcium chloride, calcium bromide, calcium nitrate, calcium citrate, calcium formate, calcium acetate, calcium gluconate, calcium ascorbate, calcium lactate, calcium glycinate, calcium carbonate, calcium sulfate, calcium hydroxide or mixtures thereof.
[0025] Exemplary suitable amounts of the component (c) calcium salt used in conjunction with the claimed invention include, but are not limited to, (1) at least about 0.1%
(or >_0.1 %), (2) from about 0.2 to about 80% (or from 0.2-80%), (3) from about 0.3 to about 60% (or from 0.3-60%), (4) from about 0.4 to about 40% (or from 0.4-40%), (5) from about 0.45 to about 20% (or from 0.45-20%), and (6) from about 0.5 to about 10% (or from 0.5-10%).
[0026] It should be noted that whatever the amount of the component (c) calcium salt, the total amount of the final claimed antiperspirant composition (including any optional or other ingredients) cannot exceed 100%.
[0027] After any optional ingredients in the claimed antiperspirant composition of the claimed invention, water comprises the remainder thereof. It should be noted that whatever the amount of all the ingredients of the claimed composition including water (or any optional ingredients), the total amount of the final claimed antiperspirant composition cannot exceed 100%. In fact, the total of all the ingredients of the claimed composition (including any optional ingredients present) must total to 100%.
[0028] An exemplary optional component of the claimed antiperspirant composition may be one or more water soluble alcohol(s). Suitable examples of water soluble alcohol(s) for use with the claimed invention include, but are not limited to, C2-C8 alcohols, C2-C3 alcohols, ethanol, glycol (G), propylene glycol (PG), dipropylene glycol (DG), tripropylene glycol (TG) or mixtures thereof.
[0029] Exemplary suitable amounts of the optional water soluble alcohol used in conjunction with the claimed invention include, but are not limited to, (1) from about 0 to about 40% (or 0-40%), (2) from about 2 to about 35% (or from 2-35%), (3) from about 4 to about 30% (or from 4-30%), (4) from about 6 to about 25% (or from 6-25%), (5) from about 8 to about 20% (or from 8-20%), and (6) from about 10 to about 15% (or from 10-15%).
[0030] Optionally, glycine may be included in the claimed antiperspirant composition. Exemplary suitable amounts of the optional glycine used in conjunction with the claimed invention include, but are not limited to, (1) from about 0 to about 40% (or 0-40%), (2) from about 1 to about 30% (or from 1-30%), (3) from about 2 to about 20% (or from 2-2%), and (4) from about 4 to about 50% (or from 4-50%), (5) from about 6 to about 20% (or from 6-20%), and (6) from about 8 to about 10% (or from 8-10%).
[0031] Other optional ingredients such as fragrance(s), color(s), dye(s), pigment, etc.
maybe included in the claimed antiperspirant composition. See Handbook of Cosmetic Science and Technology, Editors - A. Bard, M. Paye and H. Maibach, Marcel Dekker, Inc., New York (2001); Antiperspirants and Deodorants, Editors - K. Laden and C.
Pelger, Cosmetic Science and Technology Series/Volume 7, Marcel Dekker, Inc., New York (1988);
and Antiperspirants and Deodorants, 2nd Edition, Editor - K Laden, Cosmetic Science and Technology Series/Volume 20, Marcel Dekker, Inc., New York (1999).
[0032] The claimed antiperspirant composition may be provided in various forms including, but not limited to, aerosol, gels, creams, solid stick, semi-solid stick, powder, liquid, emulsion, suspension, dispersion and the like. Preferably, the form is either a stick, semi-solid stick, liquid or powder. More preferably the form is either a liquid or a powder.
[0033] Also, the particular form of the claimed antiperspirant composition is preferably provided in a suitable container such as an aerosol can (aerosol), tube or container with porous cap (gel), roll-on or bottle (liquid), container with open end (stick, pad or wipe) and the like - whatever is suitable for the particular exemplary form. Of course, the claimed invention is claimed as the composition itself and does not require that it be dispensed or provided in a suitable container to fall within the scope of the appended claims.
[0034] Given the exemplary amounts of the foregoing components listed, it should be noted that the combination of the ingredients of the claimed antiperspirant composition should be sufficient to increase the "first ratio" by at least about (1) 0.5, (2) 0.8, (3) 1, (4) 1.5, (5) 2, (6) 2.5, (7) 3, (8) 3.5, (9) 4, or (10) 4.5, respectively, when compared to that of a comparable composition without both the betaine and calcium salt components.
Likewise, it is desired that the ingredients of the claimed antiperspirant composition should be sufficient to increase the "first ratio" (11) from about 0.5 to about 10, (12) from about 0.8 to about 8, (13) from about 1 to about 6, or (14) from about 1 to about 4, respectively, when compared to that of a comparable composition without both the betaine and calcium salt components.
[0035] Given the exemplary amounts of the foregoing components listed, it should be noted that the combination of the ingredients of the claimed antiperspirant composition should be sufficient to decrease the "second ratio" to less than about (1) 0.4, (2) 0.35, (3) 0.3, (4) 0.25, (5) 0.2, (6) 0.15, (7) 0.1, (8) 0.05, (9) 0.04, (10) 0.03, (11) 0.02, or (12), 0.01, respectively, when compared to that of a comparable composition without both the betaine and calcium salt components. Preferably, according to one embodiment, the claimed antiperspirant has a "second ratio" of 0.
[0036] Given the exemplary amounts of the foregoing components listed, it should be noted that the combination of the ingredients of the claimed antiperspirant composition should be sufficient to increase the "27A1 NMR peak intensity at 63.5ppm" by at least about (1) 20% (note peak intensity is not weight %), (2) 100%, (3) 200%, (4) 300%, (5) 400%, (6) 00%, (7) 600%, (8) 700%, (9) 800, or (10) 900, respectively, when compared to that of a comparable composition without both the betaine and calcium salt components.
Additional Examples Analytical Method for Examples a. Size exclusion chromatography ("SEC"):
(0037] Size exclusion chromatography ("SEC") or gel permeation chromatography ("GPC") are methods frequently used for obtaining information on polymer distribution in antiperspirant salt solutions. With appropriate chromatographic columns, at least five distinctive groups of polymer species can be detected in a ZAG, appearing in a chromatogram as peaks 1, 2, 3, 4 and a peak known as "5,6". Peak 1 is the larger zirconium species (greater than 60 Angstroms). Peaks 2 and 3 are larger aluminum species. Peak 4 is the smaller aluminum species (aluminum oligomers) and has been correlated with enhanced efficacy for both ACH and ZAG salts. Peak 5,6 is the smallest aluminum species. The relative retention time ("Kd") for each of these peaks varies depending on the experimental conditions. This method is also applicable to ZAB (zirconium-aluminum-betaine) salts. Data for Table A was obtained using the SEC method described in an issued patent owned by the same company as a this case, U.S. Patent 6,066,314.
b. NMR measnrements:Sample preparation:
[00381 Samples were prepared by diluting 0.2m1 product in 0.8m1 D20 to yield solution at concentrations of 7.0%. Samples were weighted and dissolved in D20 to produce 7.0% active solutions. A blank sample, using same type of NMR tube and only contain D20, was also prepared to obtained the background signal from the NMR probe and test tubes. All NMR measurements were preformed immediately after the samples were prepared.
c. NMR experimental conditions:
10039] Bruker Avance DMX500 NMR spectrometer with a inverse broadband 5 mm probe was used for all NMR measurements, which operated at the frequency of 130.323 MHz for 27A1. Single pulse with CYCLOPS was used during all experiments with recycle delay at 3 second, RF pulse width at 17 O s at 0 db RF attenuation (which is 90 degree pulse).
Total number of scans for each data set is 1024, and the 64K data points (correspond to 1 second acquisition time) were acquired for each FID data set. The spectral width is 32679 Hz, which is equivalent to 250 ppm. The dewell time is 20 Os, which is the delay time between the end of RF pulse and the starting point of data acquisition. The magnetic field was locked by deuteratied water in all the samples. All NMR experiments were carried out at room temperature (21 C) without specific temperature control. A blank NMR
spectrum of the background was also recorded with exactly the same parameters.
d. NMR data analysis:
[0040] All NMR F1D data were processed with same parameters: FFT data size was 64K, and an exponential window function (LB=5 Hz) was applied before FFT to improve signal to noise ratio. Since the blank spectrum showed a broad background 27A1 signal at 72 ppm, it were subtracted from all spectra for real samples to produce spectra without background signal. The subtractions were performed in spectral domain, where the exact same processing parameters were used for sample data set and the background signal, especially the phase parameters. Automatic baseline corrections were also performed on all data sets after background correction. Since there were severe signal overlap from -20 to 40 ppm, line shape deconvolutions were performed on all data sets to obtain peak position, line width, and integration. Initial conditions were set with four resonance signals in this region, usually several runs at different initial conditions were necessary to obtain good T
deconvolution results. The deconvolution function in Bruker X-WinNMR (version 2.5) was used, and a mixed line shape of Lorentzian and Gaussian (low percentage) was used for all data sets.
Antiperspirant Salts with Betaine and Calcium Example 1 [0041] A solution was made by mixing 4 gm of CaC12 and 2 gm of betaine anhydrous with 20 gm (USP weight) ACH powder (Reheis CHLORHYDROL ) in water, mating the total weight 100 gm. The solution was then divided into two parts:
One part was aged at 70 oC overnight, and the second part was kept at room temperature for the same time period. The sample solutions were analyzed afterwards by the SEC method described earlier, as well as the ACH solution as control. As shown in Table 1, after being aged, the ACH
sample with CaC12 and betaine showed significant increase in Peak-4/Peak-3 ratio, especially at higher temperature.
Table 1, SEC peak distribution (RI Detector) Sample Peak-4/Peak-3 ACH (20%, USP) 0.244 ACH (20%, USP) + CaC12 (4%) + betaine (2%) 1.43 (Aged at 70 C, overnight) ACH (20%, USP) + CaCIZ (4%) + betaine (2%) 0.65 (Aged at RT, overnight) NMR analysis also indicated that the peak-4 species created by mixing ACH, CaC12, and betaine was very close to that in Reach-101, a thennally activated ACH with Al 13-mers in peak-4. The strength of NMR peak at 63.5 ppm representing the Al tetrahedron in the center of Al 13-mer increased from 0.388 to 1.0854 after the regular ACH was mixed with CaCl2 and betaine and then aged, suggesting the enhancement of Al 13-mers by this process.
Table 2. Relative peak strength of 27A1 NMR
Sample 63.5 ppm ACH 0.388 Activated ACH, Reach-101 1.000 ACH (20%, USP) + CaC12 (4%) + betaine (2%) 1.085 (Aged at 70 C, overnight) Example 2 [0042] A solution was made by mixing 5 gm of CaC12 and 2 gm of betaine anhydrous with 20 gm (USP weight) ACH powder (Reheis CHL RHYDROL ) in water, making the total weight of 100 gm. The solution was aged at room temperature, and then analyzed at different periods of time by the SEC method described earlier, with the ACH
sample solution as control. As shown in Table 2, Peak-4 kept going up over time indicated by the increasing Peak-4/Peak-3 ratio.
Table 2, SEC peak distribution (RI Detector) Sample Peak-4/Peak-3 ACH (20%, USP) 0.24 ACH (20%, USP) + CaC12 (5%) + betaine (2%) 1.49 (Aged at RT, 1 week) ACH (20%, USP) + CaCl2 (5%) + betaine (2%) 1.72 (Aged at RT, 1 months) ACH (20%, USP) + CaC12 (5%) + betaine (2%) 2.35 (Aged at RT, 2 months) ACH (20%, USP) + CaCl2 (5%) + betaine (2%) 3.09 (Aged at RT, 6 months) Example 3 [0043] Different amount of CaC12 and betaine anhydrous were added into AZP-955 solution, a glycine free AI-Zr-chlorohydrex made by Reheis, Inc., to form four sample solutions with concentrations of the ingredients shown in Table 3. The sample solutions were aged at 45 oC a week afterwards, and then checked by SEC for polymer size distribution profile. Table 3 exhibits the peak ratios of peak-l/(peak-2 + peak-3 + peak-4 + peak-5) and Peak-4/peak-3, measuring large zirconium polymer species and aluminum 13-mers, or peak-4 species, respectively.
[0044] Obviously, both betaine and Ca++ ions were needed to boost peak-4 species, or aluminum 13-mers, in the sample solutions: The samples with both showed considerable increase in peak-4/peak-3 ratio, while the one with only betaine or CaC12 did not have any positive change in the ratio after being aged. Furthermore, dose response effect of CaC12 was clearly demonstrated in this example: The sample with higher level of Ca++
(6.54% of CaC12) presented a much higher peak-4/peak-3 ratio than the one with lower level of Ca++
(2.17% CaC12).
[0045] The effect of betaine in stabilizing zirconium species was also demonstrated in this example: All the sample solutions with the presence of betaine showed detectable reduction in peak-1/(peak-2 + peak-3 + peak-4 + peak-5) ratio, indicating small zirconium species being stabilized.
Table 3, SEC peak distribution (RI Detector) Sample Peak-1/(P2+P3+P4+P5) Peak-4/Peak-3 AZP-955 (18.9%) as control 0.38 0.29 AZP-955 (18.9%) + CaC12 (2.17%) + 0.26 0.85 betaine (3.3%) AZP-955 (18.9%) + CaC12 (6.54%) + 0.27 1.55 betaine (3.3%) AZP-955 (18.9%) + CaC12 (0%) + 0.23 0.25 betaine (3.3%) AZP-955 (18.9%) + CaC12 (2.17%) + 0.43 0.28 betaine (0%) Example 4 [0046] Samples were made by adding CaC12 and water into ZAB-317321-I, or ZAB-317321-II aqueous solution, the Reheis prepared Zr-Al-Chlorohydrex-betaine AP
salt with betaine/zirconium molar ratio of 0.82, or 1.32 respectively, to come out with the solution samples with concentration of ingredients listed in table 4. The samples were then aged for a month at room temperature.
[0047] Table 4 presents the SEC results in peak ratios of peak-1/(peak-2 +
peak-3 +
peak-4 + peak-5) and Peak-4/peak-3, clearly revealing the effect of combination of betaine and Ca++ on zirconium polymers and peak-4 species respectively. The samples with higher betaine level, betaine/zirconium of 1.23, exhibited lower peak ratios of peak-1/(peak-2 +
peak-3 + peak-4 + peak-5), suggesting more stabilized small zirconium species.
[0048] The trend was equally evident with regard to peak-4 species: The sample with the highest level of both Ca++ and betaine, 6.54% of CaC12 and betaine/zirconium ratio of 1.23, showed the highest peak-4/peak-3 ratio of 1.73, whereas the ones of lower levels of betaine and zirconium revealed lower peak-4/peak-3 ratios accordingly.
[0049] In addition, this example further proved that if without Ca++, betaine alone would not boost peak-4 species. The two samples with different level of betaine, while without Ca++, exhibited identical peak-4/peak-3 ratios.
Table 4, SEC peak distribution (RI Detector) Sample Peak-1/(P2+P3+P4+P5) Peak-4/Peak-ZAB-317321-I 0.17 0.27 (betaine/Zr=0.82) --19% solution ZAB-317321-I 0.17 0.57 (betaine/Zr=0.82) --19% solution +CaC12(2.17%) ZAB-317321-I 0.17 0.75 (betaine/Zr=0.82) --19% solution + CaC12 (6.54 %) ZAB-317321-II 0.03 0.27 (betaine/Zr=1.23) --19% solution ZAB-317321-II 0.03 0.94 (betaine/Zr=1.23) --19% solution + CaC12 (2.17 %) ZAB-317321-II 0.03 1.73 (betaine/Zr=1.23) --19% solution +CaC12(6.54%) Example 5 [0050] Dissolve 19.26 gm ZrOC12.8H20 and 8.39g betaine anhydrous in 30 gm of water to prepare an antiperspirant (AP) salt solution. After everything is dissolved, add ACH
powder (22.65 g of Chlorhydrol from Reheis Chemical Co., Berkeley Heights, NJ) and 12 gm of CaCl2.2H20 into the solution with additional water so that the total weight of the solution reaches 100 gm. Shake and/or stir the solution until the solution becomes clear.
[0051] Such 30% salt solution (anhydrous basis) will have the following composition:
Al/Zr = 3.5 Metal/Cl =1.2 betaine/Zr = 1.2 Ca/betaine = 3.2 Al: 5.64% 0.209 Mole Zr: 5.45% 0.0597 Mole Cl: 7.95% 0.224 Mole betaine: 8.39% 0.0716 Mole CaC12 9.06% 0.082 Mole Optionally, spray dry or freeze-dry the solution to make a powder sample.
Example 6 [0052] Dissolve 19.26 g ZrOC12.8H20 in 49.6 gin of water and then add 5.36g betaine anhydrous to prepare and AP salt solution. After everything is dissolved, add ACH
powder (22.65 gin of Chlorhydrol from Reheis) and 12 gm of CaC12.2H20 into the solution with additional DI water so that the total weight of the solution reaches 100 gm. Shake and/or stir the solution until it is clear.
[0053] Such 30% salt solution (anhydrous basis) will have the following composition:
Al/Zr =3.5 Metal/Cl =1.2 betaine/Zr = 0.76 Ca/betaine = 5.0 Al: 5.64% 0.209 Mole Zr: 5.45% 0.0597 Mole Cl: 7.95% 0.224 Mole betaine: 5.36% 0.0457 Mole CaC12 9.06% 0.082 Mole Optionally, spray dry or freeze-dry the solution to make a powder sample.
Example 7 [0054] Dissolve 19.26 g of ZrOC12.8H20 in 40 gm of distilled water and then add 9.68 g of betaine monohydrate to prepare an AP salt solution. After everything is dissolved, ad ACH powder (22.65 g of Chlorhydrol from Reheis) and 5 gm of CaC12.2H20 to the solution with additional DI water so that the total weight of the solution reaches 100 gm.
Shake and/or stir the solution until a 30% salt solution (anhydrous basis) is obtained.
[0055] Such 30% salt solution (anhydrous basis) will have the following composition:
Al/Zr = 3.5 Metal/Cl =1.2 betaine/Zr = 1.2 Ca/betaine = 3.2 Al: 5.64% 0.209 Mole Zr: 5.45% 0.0597 Mole Cl: 7.95% 0.224 Mole betaine: 8.39% 0.0716 Mole CaC12 9.06% 0.082 Mole Optionally, spray dry or freeze-dry the solution to make a powder sample.
Example 6 [0052] Dissolve 19.26 g ZrOC12.8H20 in 49.6 gin of water and then add 5.36g betaine anhydrous to prepare and AP salt solution. After everything is dissolved, add ACH
powder (22.65 gin of Chlorhydrol from Reheis) and 12 gm of CaC12.2H20 into the solution with additional DI water so that the total weight of the solution reaches 100 gm. Shake and/or stir the solution until it is clear.
[0053] Such 30% salt solution (anhydrous basis) will have the following composition:
Al/Zr =3.5 Metal/Cl =1.2 betaine/Zr = 0.76 Ca/betaine = 5.0 Al: 5.64% 0.209 Mole Zr: 5.45% 0.0597 Mole Cl: 7.95% 0.224 Mole betaine: 5.36% 0.0457 Mole CaC12 9.06% 0.082 Mole Optionally, spray dry or freeze-dry the solution to make a powder sample.
Example 7 [0054] Dissolve 19.26 g of ZrOC12.8H20 in 40 gm of distilled water and then add 9.68 g of betaine monohydrate to prepare an AP salt solution. After everything is dissolved, ad ACH powder (22.65 g of Chlorhydrol from Reheis) and 5 gm of CaC12.2H20 to the solution with additional DI water so that the total weight of the solution reaches 100 gm.
Shake and/or stir the solution until a 30% salt solution (anhydrous basis) is obtained.
[0055] Such 30% salt solution (anhydrous basis) will have the following composition:
Al/Zr=3.5 M/C1=1.2 betaine/Zr=1.2Ca/betaine = 1.32 Al: 5.64% 0.209 Mole Zr: 5.45% 0.0597 Mole Cl: 7.95% 0.224 Mole Betaine: 8.39% 0.0716 Mole CaC12 3.77% 0.034 Mole Spray dry or freeze-dry the solution to make a powder sample if needed.
Example 8 [0056] Dissolve 100 gm Zr(OH)2CO3 . Zr02 in 400 gm of distilled water and then add 100 gm of betaine hydrochloride to prepare an AP salt solution. After every thing is dissolved, add ACH (226.5 gm of Chlorhydrol from Reheis) and 50 gm of CaCl2 .2H20 to the solution, as well as some additional water to make the total solution of 1000 gm. Shake and/or stir the solution of 24% (anhydrous) until it is clear. Such 24% salt solution (anhydrous basis) will have the following composition:
Al/Zr = 3.2 Metal/Cl = 1.6 betaine/Zr =1.9 Al: 5.64% 2.09 Zr: 5.92% 0.649 Cl: 6.10% 1.72 betaine: 7.63 % 0.65 CaC12 1.36 % 0.123 Mole Spray dry or freeze-dry the solution to make a- powder sample if needed.
Example 9 [0057] Dissolve 60 gm Zr(OH)2CO3. Zr02 in 101gm of HC1 solution (37%) and 400 gin of distilled water and then add 100 gm of betaine hydrochloride to prepare an AP salt solution. After every thing is dissolved, add ACH (226.5 gm of Chlorhydrol from Reheis) and 50 gm of CaC12.2H20 to the solution, as well as some water to make the total solution 1000 gm. Shake and/or stir the solution of 26.3 % (anhydrous) until it is clear. Such 26.3%
salt solution (anhydrous basis) will have the following composition:
Example 8 [0056] Dissolve 100 gm Zr(OH)2CO3 . Zr02 in 400 gm of distilled water and then add 100 gm of betaine hydrochloride to prepare an AP salt solution. After every thing is dissolved, add ACH (226.5 gm of Chlorhydrol from Reheis) and 50 gm of CaCl2 .2H20 to the solution, as well as some additional water to make the total solution of 1000 gm. Shake and/or stir the solution of 24% (anhydrous) until it is clear. Such 24% salt solution (anhydrous basis) will have the following composition:
Al/Zr = 3.2 Metal/Cl = 1.6 betaine/Zr =1.9 Al: 5.64% 2.09 Zr: 5.92% 0.649 Cl: 6.10% 1.72 betaine: 7.63 % 0.65 CaC12 1.36 % 0.123 Mole Spray dry or freeze-dry the solution to make a- powder sample if needed.
Example 9 [0057] Dissolve 60 gm Zr(OH)2CO3. Zr02 in 101gm of HC1 solution (37%) and 400 gin of distilled water and then add 100 gm of betaine hydrochloride to prepare an AP salt solution. After every thing is dissolved, add ACH (226.5 gm of Chlorhydrol from Reheis) and 50 gm of CaC12.2H20 to the solution, as well as some water to make the total solution 1000 gm. Shake and/or stir the solution of 26.3 % (anhydrous) until it is clear. Such 26.3%
salt solution (anhydrous basis) will have the following composition:
Al/Zr = 5.4 Metal/Cl = 1.2 betaine/Zr = 1.9 Al: 5.64% 2.09 Zr: 3.55 % 0.389 Cl: 7.32 % 2.06 betaine: 7.63 % 0.65 CaC12: 3.77 % 0.34 Spray dry or freeze-dry the solution to make a powder sample if needed.
Example 10 [0058] Dissolve 118.1 gm ZrOCO3. 7.56H20 in 101gm of HC1 solution (37%) and 400 gm of distilled water and then add 100 gm of betaine hydrochloride to prepare an AP salt solution. After every thing is dissolved, add ACH (226.5 gm of Chlorhydrol from Reheis) and 50 gm of CaC12. 2H20 to the solution, as well as some water to make the total solution 1000 gm. Shake and/or stir the solution of 26.3 % (anhydrous) until it is clear. Such 26.3%
salt solution (anhydrous basis) will have the following composition:
Al/Zr = 5.4 Metal/Cl =1.2 betaine/Zr =1.9 Al: 5.64% 2.09 Zr: 3.55% 0.389 Cl: 7.32 % 2.06 betaine: 7.63 % 0.65 CaCJ2: 3.77 % 0.34 Spray dry or freeze-dry the solution to make a powder sample if needed.
Example 11 [0059] Dissolve 118.1 gm ZrOCO3. 7.56H20 in 73.3gm of HCl solution (37%) and 400 gm of distilled water and then add 100 gm of betaine hydrochloride. After every thing is dissolved, add ACH (226.5 gm of Chlorhydrol from Reheis) and 50 gm of CaCl2 .
2H20 to the solution, as well as some water to make the total solution 1000 gm. Shake or stir the 26.3 % (anhydrous) solution until it is clear. Such 26.3% salt solution (anhydrous basis) will have the following composition:
Al/Zr = 5.4 Metal/C1= 1.4 betaine/Zr =1.9 Al: 5.64 % 2.09 Zr: 3.55 % 0.389 Cl: 6.27 % 1.77 betaine: 7.63 % 0.65 CaC12: 3.77 % 0.34 Spray dry or freeze-dry the solution to make a powder sample if needed.
Example 12 [0060] Dissolve 30 g ADCH in 54 gm of DI water to prepare a solution of aluminum dichlorohydrex (ADCH, Westchlor 100, 38%). After the solution is mixed and becomes clear, add 8 gm of anhydrous betaine and 8 gm of CaC12. 2H20. Mix the solution at room temperature until clear. The final solution will have a betaine/aluminum molar ratio of 0.61 and a Ca/betaine ratio of 1.41.
Example 13 [0061] Mix a 31% solution of zirconium oxychloride (ZrOC12 ) with 8 gm anhydrous betaine and 12gm of CaC12.2H2O and stir at room temperature until clear. The final solution will have a betaine/zirconium molar ratio of 0.43, and a Ca/betaine ratio of 2.11, and a zirconium/chloride ratio of 0.50.
Example 14 [0062] An aqueous solution was made a by adding 1.5 gm CaC12. 2H20, 7.0 gm of ethanol (200 proof) and 6.8 gm of distilled water into a ZAB (Zirconium-Aluminum-Chlorohydrex with betaine) aqueous solution (29.5% anhydrous, betaine/Zr=1.2, M/C1=1.1) prepared by Reheis Co. The solution was then stirred well and ready to be used in all solution based formulas.
Example 10 [0058] Dissolve 118.1 gm ZrOCO3. 7.56H20 in 101gm of HC1 solution (37%) and 400 gm of distilled water and then add 100 gm of betaine hydrochloride to prepare an AP salt solution. After every thing is dissolved, add ACH (226.5 gm of Chlorhydrol from Reheis) and 50 gm of CaC12. 2H20 to the solution, as well as some water to make the total solution 1000 gm. Shake and/or stir the solution of 26.3 % (anhydrous) until it is clear. Such 26.3%
salt solution (anhydrous basis) will have the following composition:
Al/Zr = 5.4 Metal/Cl =1.2 betaine/Zr =1.9 Al: 5.64% 2.09 Zr: 3.55% 0.389 Cl: 7.32 % 2.06 betaine: 7.63 % 0.65 CaCJ2: 3.77 % 0.34 Spray dry or freeze-dry the solution to make a powder sample if needed.
Example 11 [0059] Dissolve 118.1 gm ZrOCO3. 7.56H20 in 73.3gm of HCl solution (37%) and 400 gm of distilled water and then add 100 gm of betaine hydrochloride. After every thing is dissolved, add ACH (226.5 gm of Chlorhydrol from Reheis) and 50 gm of CaCl2 .
2H20 to the solution, as well as some water to make the total solution 1000 gm. Shake or stir the 26.3 % (anhydrous) solution until it is clear. Such 26.3% salt solution (anhydrous basis) will have the following composition:
Al/Zr = 5.4 Metal/C1= 1.4 betaine/Zr =1.9 Al: 5.64 % 2.09 Zr: 3.55 % 0.389 Cl: 6.27 % 1.77 betaine: 7.63 % 0.65 CaC12: 3.77 % 0.34 Spray dry or freeze-dry the solution to make a powder sample if needed.
Example 12 [0060] Dissolve 30 g ADCH in 54 gm of DI water to prepare a solution of aluminum dichlorohydrex (ADCH, Westchlor 100, 38%). After the solution is mixed and becomes clear, add 8 gm of anhydrous betaine and 8 gm of CaC12. 2H20. Mix the solution at room temperature until clear. The final solution will have a betaine/aluminum molar ratio of 0.61 and a Ca/betaine ratio of 1.41.
Example 13 [0061] Mix a 31% solution of zirconium oxychloride (ZrOC12 ) with 8 gm anhydrous betaine and 12gm of CaC12.2H2O and stir at room temperature until clear. The final solution will have a betaine/zirconium molar ratio of 0.43, and a Ca/betaine ratio of 2.11, and a zirconium/chloride ratio of 0.50.
Example 14 [0062] An aqueous solution was made a by adding 1.5 gm CaC12. 2H20, 7.0 gm of ethanol (200 proof) and 6.8 gm of distilled water into a ZAB (Zirconium-Aluminum-Chlorohydrex with betaine) aqueous solution (29.5% anhydrous, betaine/Zr=1.2, M/C1=1.1) prepared by Reheis Co. The solution was then stirred well and ready to be used in all solution based formulas.
Claims (41)
1. An antiperspirant composition comprising:
(a) an antiperspirant salt selected from the group consisting of an aluminum antiperspirant salt, an aluminum-zirconium antiperspirant salt, and a mixture thereof, wherein the aluminum antiperspirant salt is at least one salt selected from aluminum chlorohydrate, aluminum dichlorohydrate, aluminum sesquichlorohydrate, aluminum chlorohydrex propylene glycol, aluminum dichlorohydrex propylene glycol, aluminum sesquichlorohydrex propylene glycol, aluminum chlorohydrex polyethylene glycol, aluminum dichlorohydrex polyethylene glycol, and aluminum sesquichlorohydrex polyethylene glycol;
(b) a trimethylglycine component selected from the group consisting of trimethylglycine, trimethylglycine hydrochloride, and a mixture thereof;
and (c) a calcium salt wherein said calcium salt component (c) together with said trimethylglycine component (b) is provided in an amount sufficient to increase a ratio of an HPLC
peak 4 area to peak 3 area, said peak 4 area being proportional to an amount of a polymer of said antiperspirant salt and said peak 3 area being proportional to an amount of a larger polymer of said antiperspirant salt.
(a) an antiperspirant salt selected from the group consisting of an aluminum antiperspirant salt, an aluminum-zirconium antiperspirant salt, and a mixture thereof, wherein the aluminum antiperspirant salt is at least one salt selected from aluminum chlorohydrate, aluminum dichlorohydrate, aluminum sesquichlorohydrate, aluminum chlorohydrex propylene glycol, aluminum dichlorohydrex propylene glycol, aluminum sesquichlorohydrex propylene glycol, aluminum chlorohydrex polyethylene glycol, aluminum dichlorohydrex polyethylene glycol, and aluminum sesquichlorohydrex polyethylene glycol;
(b) a trimethylglycine component selected from the group consisting of trimethylglycine, trimethylglycine hydrochloride, and a mixture thereof;
and (c) a calcium salt wherein said calcium salt component (c) together with said trimethylglycine component (b) is provided in an amount sufficient to increase a ratio of an HPLC
peak 4 area to peak 3 area, said peak 4 area being proportional to an amount of a polymer of said antiperspirant salt and said peak 3 area being proportional to an amount of a larger polymer of said antiperspirant salt.
2. The composition of claim 1, further comprising water.
3. The antiperspirant composition of claim 1 or 2, wherein said ratio of an HPLC peak 4 area to peak 3 area is increased to at least 0.5.
4. The antiperspirant composition of any one of claims 1 to 3, wherein said ratio of an HPLC peak 4 area to peak 3 area is increased to at least 1.
5. The antiperspirant composition of any one of claims 1 to 4, wherein said ratio of an HPLC peak 4 area to peak 3 area is increased to at least 2.
6. The antiperspirant composition of any one of claims 1 to 5, wherein said ratio of an HPLC peak 4 area to peak 3 area is increased to at least 3.
7. The antiperspirant composition of any one of claims 1 to 6, wherein said ratio of an HPLC peak 4 area to peak 3 area is increased to at least 4.
8. The antiperspirant composition of any one of claims 1 to 7, wherein said antiperspirant salt is said aluminum-zirconium antiperspirant salt, wherein said calcium salt component (c) together with said trimethylglycine component (b) is provided in an amount sufficient to decrease a ratio of the peak area of HPLC
peak 1 to a sum of the peak areas of HPLC peaks 2, 3, 4 and 5, said peak area of HPLC peak 1 being proportional to a polymer of said antiperspirant salt and said sum of the peak areas of HPLC peaks 2, 3, 4 and 5 being proportional to a sum of smaller polymers of said antiperspirant salt.
peak 1 to a sum of the peak areas of HPLC peaks 2, 3, 4 and 5, said peak area of HPLC peak 1 being proportional to a polymer of said antiperspirant salt and said sum of the peak areas of HPLC peaks 2, 3, 4 and 5 being proportional to a sum of smaller polymers of said antiperspirant salt.
9. The antiperspirant composition of claim 8, wherein said ratio of the peak area of HPLC peak 1 to the sum of the peak areas of HPLC peaks 2, 3, 4 and 5 is decreased to less than 0.4.
10. The antiperspirant composition of claim 8 or 9, wherein said ratio of the peak area of HPLC peak 1 to the sum of the peak areas of HPLC peaks 2, 3, and 5 is decreased to less than 0.3.
11. The antiperspirant composition of any one of claims 8 to 10, wherein said ratio of the peak area of HPLC peak 1 to the sum of the peak areas of HPLC
peaks 2, 3, 4 and 5 is decreased to less than 0.2.
peaks 2, 3, 4 and 5 is decreased to less than 0.2.
12. The antiperspirant composition of any one of claims 8 to 11, wherein said ratio of the peak area of HPLC peak 1 to the sum of the peak areas of HPLC
peaks 2, 3, 4 and 5 is decreased to less than 0.1
peaks 2, 3, 4 and 5 is decreased to less than 0.1
13. The antiperspirant composition of any one of claims 8 to 12, wherein said ratio of the peak area of HPLC peak 1 to the sum of the peak areas of HPLC
peaks 2, 3, 4 and 5 is 0.
peaks 2, 3, 4 and 5 is 0.
14. The antiperspirant composition of any one of claims 1 to 13, wherein said calcium salt is selected from the group consisting of calcium chloride, calcium bromide, calcium nitrate, calcium citrate, calcium formate, calcium acetate, calcium gluconate, calcium ascorbate, calcium lactate, calcium glycinate, calcium carbonate, calcium sulfate, calcium hydroxide and mixtures thereof.
15. The antiperspirant composition of any one of claims 1 to 14, wherein said calcium salt component (c) together with said trimethylglycine component (b) is provided in an amount sufficient to increase an 27 Al NMR peak intensity at 63.5 ppm.
16. The antiperspirant composition of claim 15 wherein said increase in said 27 Al NMR peak intensity is at least 20%.
17. The antiperspirant composition of claim 15 or 16 wherein said increase in said 27 Al NMR peak intensity is at least 100%.
18. The antiperspirant composition of any one of claims 15 to 17 wherein said increase in said 27 Al NMR peak intensity is at least 300%.
19. The antiperspirant composition of any one of claims 15 to 18 wherein said increase in said 27 Al NMR peak intensity is at least 500%.
20. The antiperspirant composition of any one of claims 15 to 19 wherein said increase in said 27 Al NMR peak intensity is at least 700%.
21. The antiperspirant composition of any one of claims 15 to 20 wherein said increase in said 27 Al NMR peak intensity is at least 900%.
22. The antiperspirant composition of any one of claims 1 to 21, wherein the antiperspirant salt is in the range from 5 - 85 weight % based on a total weight of said antiperspirant composition.
23. The antiperspirant composition of any one of claims 1 to 22, wherein the antiperspirant salt is in the range from about 10 - 60 weight % based on the total weight of said antiperspirant composition.
24. The antiperspirant composition of any one of claims 1 to 23, wherein the antiperspirant salt is in the range from about 15 - 35 weight % based on the total weight of said antiperspirant composition.
25. The antiperspirant composition of any one of claims 1 to 24, wherein the trimethylglycine component (b) is present in an amount of at least 0.1 weight % based on a total weight of said composition.
26. The antiperspirant composition of any one of claims 1 to 25, wherein the trimethylglycine component (b) is in the range from about 0.5 - 40 weight %
based on the total weight of said composition.
based on the total weight of said composition.
27. The antiperspirant composition of any one of claims 1 to 26, wherein the trimethylglycine component (b) is in the range from about 2.0 - 30 weight %
based on a total weight of said composition.
based on a total weight of said composition.
28. The antiperspirant composition of any one of claims 1 to 27, wherein the trimethylglycine component (b) is in the range from about 4.0 - 20 weight %
based on the total weight of said composition.
based on the total weight of said composition.
29. The antiperspirant composition of any one of claims 1 to 28, wherein the calcium salt component (c) is present in an amount of at least 0.1 weight %
based on a total weight of said composition.
based on a total weight of said composition.
30. The antiperspirant composition of any one of claims 1 to 29, wherein the calcium salt component (c) is in the range from about 0.2 - 80 weight %
based on the total weight of said composition.
based on the total weight of said composition.
31. The antiperspirant composition of any one of claims 1 to 30, wherein the calcium salt component (c) is in the range from about 0.4 - 40 weight %
based on the total weight of said composition.
based on the total weight of said composition.
32. The antiperspirant composition of any one of claims 1 to 31, wherein the calcium salt component (c) is in the range from about 0.5 - 10 weight %
based on the total weight of said composition.
based on the total weight of said composition.
33. The antiperspirant composition of any one of claims 1 to 32, further comprising a water soluble alcohol.
34. The antiperspirant composition of claim 33, wherein said water soluble alcohol is a C2-C8 alcohol.
35. The antiperspirant composition of claim 33 or 34, where said water soluble alcohol is ethanol.
36. The antiperspirant composition of claim 35, wherein said water soluble alcohol is selected from the group consisting of glycol, propylene glycol, dipropylene glycol, tripropylene glycol and mixtures thereof.
37. The antiperspirant composition of any one of claims 1 to 36, further comprising glycine in an amount greater than 0 to 40 weight % based on a total weight of said composition.
38. The antiperspirant composition of any one of claims 1 to 37, wherein said glycine is provided in an amount from about 1 - 30 weight % based on the total weight of said composition.
39. The antiperspirant composition of any one of claims 1 to 38, wherein said glycine is provided in an amount from about 2 - 20 weight % based on the total weight of said composition.
40. The antiperspirant composition of any one of claims 1 to 39, wherein said glycine is provided in an amount from about 8 - 10% based on the total weight of said composition.
41. The antiperspirant composition of any one of claims 1 to 40, wherein the composition is in the form of a powder, a liquid, a gel, or a solid.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65407005P | 2005-02-18 | 2005-02-18 | |
| US60/654,070 | 2005-02-18 | ||
| US11/348,499 US7704531B2 (en) | 2005-02-18 | 2006-02-06 | Enhanced efficacy aluminum or aluminum-zirconium antiperspirant salt compositions containing calcium salt(s) and betaine |
| US11/348,499 | 2006-02-06 | ||
| PCT/US2006/005054 WO2006091417A1 (en) | 2005-02-18 | 2006-02-14 | Enhanced efficacy aluminum or aluminum-zirconium antiperspirant salt compositions containing calcium salt(s) and betaine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2598350A1 CA2598350A1 (en) | 2006-08-31 |
| CA2598350C true CA2598350C (en) | 2011-04-19 |
Family
ID=36564791
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2598350A Expired - Fee Related CA2598350C (en) | 2005-02-18 | 2006-02-14 | Enhanced efficacy aluminum or aluminum-zirconium antiperspirant salt compositions containing calcium salt(s) and betaine |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US7704531B2 (en) |
| EP (1) | EP1853222B1 (en) |
| AR (1) | AR053547A1 (en) |
| AU (1) | AU2006216930B2 (en) |
| BR (1) | BRPI0607766A2 (en) |
| CA (1) | CA2598350C (en) |
| ES (1) | ES2476421T3 (en) |
| MX (1) | MX2007010017A (en) |
| PL (1) | PL1853222T3 (en) |
| RU (1) | RU2007134576A (en) |
| WO (1) | WO2006091417A1 (en) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040109833A1 (en) | 2002-12-09 | 2004-06-10 | Xiaozhong Tang | High efficacy, low irritation aluminum salts and related products |
| CL2006003116A1 (en) * | 2005-11-16 | 2008-02-29 | Colgate Palmolive Co | ANTI-TRANSPIRING COMPOSITION THAT INCLUDES AT LEAST ONE CHOSEN ALUMINUM SALT, ZIRCONY ALUMINUM, A COMPLEX ALUMINUM SALT OR A COMPLEX ALUMINUM-ZIRCONY SALT, A HYDROXIACIDE AND AN ACID COMPOUND OF QUATERNARY AMMONIUM; PROCESS TO PREPARE |
| WO2008063188A2 (en) * | 2006-11-03 | 2008-05-29 | Reheis, Inc. | Betaine with calcium and/or strontium antiperspirants |
| US9789038B2 (en) | 2007-02-02 | 2017-10-17 | Colgate-Palmolive Company | Antiperspirant/deodorant compositions |
| US7976828B2 (en) | 2007-02-02 | 2011-07-12 | Colgate-Palmolive Company | Antiperspirant/deodorant composition |
| US8257689B2 (en) * | 2007-12-12 | 2012-09-04 | Colgate-Palmolive Company | Antiperspirant active compositions having SEC chromatogram exhibiting high SEC peak 4 intensity |
| US20100202993A1 (en) * | 2007-12-12 | 2010-08-12 | Long Pan | Antiperspirant Active Compositions Having SEC Chromatogram Exhibiting High SEC Peak 4 Intensity |
| WO2011016807A1 (en) * | 2009-08-06 | 2011-02-10 | Colgate-Palmolive Company | Method of making an antiperspirant active composition having sec chromatogram exhibiting high sec peak 4 intensity |
| ES2585741T3 (en) * | 2009-09-30 | 2016-10-07 | Colgate-Palmolive Company | Antiperspirant composition |
| BR112012006665B1 (en) * | 2009-09-30 | 2018-01-16 | Colgate-Palmolive Company | COMPOSITIONS AND METHOD UNDERSTANDING TO APPLY THESE COMPOSITIONS |
| AR078677A1 (en) | 2009-10-20 | 2011-11-23 | Colgate Palmolive Co | ANTITRANSPIRING COMPOSITION THAT REDUCES OR ELIMINATES YELLOW DECOLORATION IN CLOTHING |
| MX341433B (en) | 2009-12-23 | 2016-08-18 | Colgate-Palmolive Company * | Anhydrous liquid antiperspirant/deodorant composition. |
| US9144695B2 (en) | 2010-06-01 | 2015-09-29 | Coty Inc. | Antiperspirant compositions |
| EP2590532A1 (en) | 2010-07-06 | 2013-05-15 | Colgate-Palmolive Company | Personal care product and manufacture thereof |
| BR112013010694A2 (en) | 2010-11-02 | 2016-07-05 | Colgate Palmolive Co | active antiperspirant compositions and their production |
| US9463985B2 (en) | 2010-11-02 | 2016-10-11 | Colgate-Palmolive Company | Aluminum salt containing high percentage of Al30 |
| BR112013027593A2 (en) | 2011-04-26 | 2017-06-20 | Colgate Palmolive Co | antiperspirant active compositions and their manufacture |
| US9174851B2 (en) | 2011-04-26 | 2015-11-03 | Colgate-Palmolive Company | Compositions containing polyhydroxyoxoaluminum cations and manufacture thereof |
| MX2015007384A (en) | 2012-12-11 | 2015-09-16 | Colgate Palmolive Co | Antiperspirant/deodorant with alkylated polyvinylpyrrolidone. |
| EP2986272B1 (en) | 2013-04-19 | 2017-06-07 | Colgate-Palmolive Company | Aerosol antiperspirants |
| EP3295922B1 (en) * | 2013-05-20 | 2024-04-17 | Unilever IP Holdings B.V. | Antiperspirant compositions |
| MX2015016073A (en) | 2013-05-20 | 2016-03-21 | Unilever Nv | Method of manufacture of antiperspirant salts. |
| US10111817B2 (en) | 2014-07-21 | 2018-10-30 | Colgate-Palmolive Company | Antiperspirant compositions containing ethylenediamine disuccinate |
| MX368316B (en) | 2014-09-26 | 2019-09-27 | Colgate Palmolive Co | Aluminum chlorohydrate salts exhibiting high sec peak 1. |
| MX2017005488A (en) | 2014-10-27 | 2017-09-15 | Unilever Nv | Anhydrous antiperspirant compositions. |
| WO2016066528A1 (en) | 2014-10-27 | 2016-05-06 | Unilever Plc | Anhydrous antiperspirant aerosol compositions |
| WO2016078991A1 (en) | 2014-11-19 | 2016-05-26 | Unilever Plc | Process of manufacture of an antiperspirant composition |
| US9867765B2 (en) * | 2014-11-19 | 2018-01-16 | Conopco, Inc. | Antiperspirant compositions |
| US10660830B2 (en) | 2015-11-06 | 2020-05-26 | Conopco, Inc. | Aerosol antiperspirant product |
| EP3370683B1 (en) | 2015-11-06 | 2019-07-24 | Unilever PLC, a company registered in England and Wales under company no. 41424 of | Antiperspirant compositions |
| MX367566B (en) | 2015-11-06 | 2019-08-27 | Unilever Nv | Aerosol antiperspirant product. |
| WO2017118507A1 (en) | 2016-01-07 | 2017-07-13 | Unilever Plc | Antiperspirant compositions |
| WO2018125030A1 (en) | 2016-12-27 | 2018-07-05 | Colgate-Palmolive Company | Extruded antiperspirant composition for improved efficacy |
| CN111432783B (en) | 2017-12-14 | 2023-05-02 | 高露洁-棕榄公司 | Antiperspirant/deodorant compositions comprising biodegradable aminocarboxylates and methods therefor |
| WO2021096518A1 (en) | 2019-11-14 | 2021-05-20 | Colgate-Palmolive Company | Personal care compositions for treating odor causing bacteria and methods for the same |
| WO2023280775A1 (en) | 2021-07-07 | 2023-01-12 | Unilever Ip Holdings B.V. | Aqueous antiperspirant compositions |
| CN117615745A (en) | 2021-07-07 | 2024-02-27 | 联合利华知识产权控股有限公司 | Process for the preparation of antiperspirant salts |
| AU2022306937A1 (en) | 2021-07-07 | 2023-12-07 | Unilever Global Ip Limited | Emulsion antiperspirant compositions |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2256505A (en) | 1939-03-25 | 1941-09-23 | William R Warner & Company Inc | Cosmetic |
| US2571030A (en) | 1950-03-15 | 1951-10-09 | Reheis Company Inc | Astringent, antiperspirant, and method of making |
| GB880261A (en) | 1957-03-13 | 1961-10-18 | Albright & Wilson Mfg Ltd | Improvements in or relating to the production of aqueous aluminium chlorhydrate gels |
| GB1054265A (en) | 1962-11-07 | 1900-01-01 | ||
| US3963833A (en) | 1972-06-02 | 1976-06-15 | Colgate-Palmolive Company | Antiperspirant composition and method containing a dihydro-benzofuran and an astringent metal salt |
| US4017599A (en) | 1973-11-23 | 1977-04-12 | Armour Pharmaceutical Company | Aluminum-zirconium anti-perspirant systems with salts of amino acids |
| US3998788A (en) | 1974-01-08 | 1976-12-21 | Armour Pharmaceutical Company | Aluminum-zirconium anti-perspirant systems with trace amounts of alkaline earth metals |
| US4025615A (en) | 1975-02-25 | 1977-05-24 | Armour Pharmaceutical Company | Antiperspirant complexes formed with alkali metal and ammonium zirconyl carbonates |
| FR2303536A1 (en) | 1975-03-11 | 1976-10-08 | Rhone Poulenc Ind | NEW ALUMINUM SALTS, THEIR PREPARATION AND THE COMPOSITIONS CONTAINING THEM |
| US4021536A (en) | 1975-04-18 | 1977-05-03 | Armour Pharmaceutical Company | Magnesium-zirconium complexes useful as antiperspirants |
| US4359456A (en) | 1976-01-14 | 1982-11-16 | Lever Brothers Company | Antiperspirant activity of basic aluminum compounds |
| GB2048229A (en) | 1979-04-20 | 1980-12-10 | Gillette Co | Aluminium Chlorhydroxide and Preparation Thereof |
| US4435382A (en) | 1980-07-14 | 1984-03-06 | Bristol-Myers Company | Anhydrous alcoholic antiperspirant suspension composition containing certain aluminum or aluminum/zirconium salt glycine complexes |
| US4331609A (en) | 1980-09-08 | 1982-05-25 | The Procter & Gamble Company | Antiperspirant composition |
| US4526780A (en) | 1981-03-09 | 1985-07-02 | Colgate-Palmolive Company | Anhydrous antiperspirant composition |
| US5102656A (en) | 1983-07-29 | 1992-04-07 | The Mennen Company | Antiperspirant creams |
| US4775528A (en) | 1983-08-16 | 1988-10-04 | The Gillette Company | Antiperspirant composition |
| US5589196A (en) | 1983-08-16 | 1996-12-31 | The Gillette Company | Antiperspirant composition |
| GB8410403D0 (en) | 1984-04-24 | 1984-05-31 | Unilever Plc | Antiperspirant product |
| US4722835A (en) | 1984-09-21 | 1988-02-02 | American Cyanamid Company | Dibenzyl monosorbitol acetal gel antiperspirant stick compositions |
| US4871525A (en) | 1986-10-24 | 1989-10-03 | Westwood Chemical Corporation | Antiperspirant composition and method of preparation |
| US5250291A (en) | 1986-12-23 | 1993-10-05 | Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. | Cosmetic product |
| GB8630723D0 (en) | 1986-12-23 | 1987-02-04 | Unilever Plc | Cosmetic product |
| US4781917A (en) | 1987-06-26 | 1988-11-01 | The Proctor & Gamble Company | Antiperspirant gel stick |
| US4816261A (en) | 1987-11-20 | 1989-03-28 | The Procter & Gamble Company | Deodorant gel stick |
| DE69117056T2 (en) | 1990-04-06 | 1996-09-12 | Procter & Gamble | Antiperspirant Gel Pen Compositions |
| US5162378A (en) | 1990-04-20 | 1992-11-10 | Revlon Consumer Products Corporation | Silicone containing water-in-oil microemulsions having increased salt content |
| CA2046170A1 (en) | 1990-07-10 | 1992-01-11 | Morton Lawrence Barr | Basic aluminum antiperspirant active materials having enhanced activity, antiperspirant active compositions containing such materials, and methods for preparation of such materials and compositions |
| NZ241567A (en) | 1991-02-13 | 1994-08-26 | Bristol Myers Squibb Co | Zirconium-aluminium-amino acid salts, and antiperspirant compositions thereof |
| US5225187A (en) | 1991-02-15 | 1993-07-06 | Somerville Technology Group, Inc. | Process for preparing concentrated aluminum-zirconium solutions |
| US5200174A (en) | 1991-05-06 | 1993-04-06 | Procter & Gamble | Gel stick antiperspirant composition containing 2-oxazolidinone derivative and process for making them |
| US5254230A (en) | 1992-07-17 | 1993-10-19 | Reheis, Inc. | Methods for preparing basic aluminum compounds with ultrasound |
| ZA945542B (en) | 1993-08-10 | 1995-05-26 | Bristol Myers Squibb Co | Novel zirconium salts and their synthesis |
| US5520907A (en) | 1994-03-22 | 1996-05-28 | Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. | Clear antiperspirant sticks |
| US5516511A (en) | 1994-05-06 | 1996-05-14 | The Procter & Gamble Company | Antiperspirant gel compositions comprising chelators |
| US5534246A (en) | 1994-08-29 | 1996-07-09 | Helene Curtis, Inc. | Topically-effective compositions |
| US5643558A (en) | 1994-11-02 | 1997-07-01 | The Gillette Company | Method of making polyhydric alcohol solutions of enhanced efficacy antiperspirant actives |
| US5653970A (en) | 1994-12-08 | 1997-08-05 | Lever Brothers Company, Division Of Conopco, Inc. | Personal product compositions comprising heteroatom containing alkyl aldonamide compounds |
| US5599533A (en) | 1994-12-15 | 1997-02-04 | Estee Lauder, Inc. | Stable water-in-oil emulsion system |
| AU4690196A (en) | 1994-12-21 | 1996-07-10 | Cosmederm Technologies | Formulations and methods for reducing skin irritation |
| US5997850C1 (en) | 1997-10-29 | 2001-11-27 | Colgate Palmolive Co | Antiperspirant actives and formulations made therefrom |
| US6042816A (en) * | 1998-08-19 | 2000-03-28 | The Gillette Company | Enhanced antiperspirant salts stabilized with calcium and concentrated aqueous solutions of such salts |
| US5955065A (en) | 1998-08-19 | 1999-09-21 | The Gillette Company | Antiperspirant compositions containing calcium salts |
| DE19855935A1 (en) | 1998-12-04 | 2000-06-08 | Beiersdorf Ag | Use of functionally substituted betaines as antiperspirants |
| DE19855934A1 (en) | 1998-12-04 | 2000-06-08 | Beiersdorf Ag | Use of betaines as antiperspirants |
| US20040228887A1 (en) | 1999-05-11 | 2004-11-18 | Champ Charles W. | Host-guest processes and formulations for delivering bio-affecting compounds |
| US6024945A (en) | 1999-07-29 | 2000-02-15 | Reheis, Inc. | Antiperspirant compositions for aerosol formulations |
| WO2001039730A1 (en) | 1999-12-02 | 2001-06-07 | Orion Corporation, Noiro | Cosmetic composition |
| US6265364B1 (en) | 1999-12-28 | 2001-07-24 | Colgate-Palmolive Company | Solid cleansing composition comprising a choline salt |
| US6436381B1 (en) | 2000-10-25 | 2002-08-20 | The Gillette Company | Aluminum-zirconium antiperspirant salts with high peak 5 al content |
| FR2828646B1 (en) | 2001-08-17 | 2004-11-26 | Oreal | ANHYDROUS ANTITRANSPIRANT STICK |
| US6726901B2 (en) | 2002-05-09 | 2004-04-27 | The Gillette Company | Stabilized antiperspirant compositions containing aluminum-zirconium salts with low M:Cl ratio |
| DE10243233A1 (en) | 2002-09-17 | 2004-04-15 | Phenion Gmbh & Co. Kg | Use of substances to protect the skin |
| US20040091436A1 (en) | 2002-11-12 | 2004-05-13 | Zijun Li | Antiperspirant compositions of enhanced efficacy containing strontium |
| US20040109833A1 (en) | 2002-12-09 | 2004-06-10 | Xiaozhong Tang | High efficacy, low irritation aluminum salts and related products |
| US6911195B2 (en) | 2002-12-16 | 2005-06-28 | The Gillette Company | Gel antiperspirant composition containing volatile linear silicone and calcium enhanced antiperspirant salt |
| US20040198998A1 (en) | 2003-04-04 | 2004-10-07 | Marian Holerca | Glycine-free antiperspirant salts with betaine for enhanced cosmetic products |
| CA2521245C (en) | 2003-04-04 | 2012-12-11 | Colgate-Palmolive Company | Glycine-free antiperspirant salts with betaine for enhanced cosmetic products |
| US7105691B2 (en) | 2003-06-26 | 2006-09-12 | Colgate-Palmolive Company | Aluminum / zirconium / glycine antiperspirant actives stabilized with Betaine |
| US6902723B2 (en) | 2003-08-14 | 2005-06-07 | The Gillette Company | Enhanced efficacy antiperspirant compositions containing strontium |
| US6923952B2 (en) | 2003-08-14 | 2005-08-02 | The Gillette Company | Enhanced efficacy antiperspirant compositions containing strontium or calcium |
| US6942850B2 (en) | 2003-08-15 | 2005-09-13 | The Gillette Company | Aqueous alcoholic antiperspirant composition containing calcium enhanced antiperspirant salt |
| GB0326181D0 (en) | 2003-11-11 | 2003-12-17 | Unilever Plc | Antiperspirant compositions |
| US7014843B2 (en) | 2004-03-24 | 2006-03-21 | Reheis, Inc. | Enhanced efficacy basic aluminum halides/metal cation salt, antiperspirants actives and compositions containing such materials and methods for making |
| US6902724B1 (en) | 2004-03-24 | 2005-06-07 | Reheis, Inc. | Enhanced efficacy basic aluminum halides, antiperspirant active compositions and methods for making |
| US7087220B2 (en) | 2004-05-28 | 2006-08-08 | Reheis, Inc. | High pH antiperspirant compositions of enhanced efficacy |
| US20070020211A1 (en) | 2005-07-22 | 2007-01-25 | Reheis, Inc. | Betaine with Calcium and/or Strontium Antiperspirants |
| CL2006003116A1 (en) | 2005-11-16 | 2008-02-29 | Colgate Palmolive Co | ANTI-TRANSPIRING COMPOSITION THAT INCLUDES AT LEAST ONE CHOSEN ALUMINUM SALT, ZIRCONY ALUMINUM, A COMPLEX ALUMINUM SALT OR A COMPLEX ALUMINUM-ZIRCONY SALT, A HYDROXIACIDE AND AN ACID COMPOUND OF QUATERNARY AMMONIUM; PROCESS TO PREPARE |
| US20070196303A1 (en) | 2006-02-17 | 2007-08-23 | Reheis, Inc. | Stable buffered aluminum compositions having high hplc bands iii and iv containing calcium/strontium |
| US20070286830A1 (en) | 2006-06-13 | 2007-12-13 | Reheis, Inc. | Aluminum compositions of enhanced efficacy having high HPLC Bands III and IV |
-
2006
- 2006-02-06 US US11/348,499 patent/US7704531B2/en not_active Expired - Fee Related
- 2006-02-14 BR BRPI0607766-8A patent/BRPI0607766A2/en not_active Application Discontinuation
- 2006-02-14 RU RU2007134576/15A patent/RU2007134576A/en unknown
- 2006-02-14 EP EP06720706.8A patent/EP1853222B1/en not_active Not-in-force
- 2006-02-14 WO PCT/US2006/005054 patent/WO2006091417A1/en active Application Filing
- 2006-02-14 MX MX2007010017A patent/MX2007010017A/en active IP Right Grant
- 2006-02-14 AU AU2006216930A patent/AU2006216930B2/en not_active Ceased
- 2006-02-14 PL PL06720706T patent/PL1853222T3/en unknown
- 2006-02-14 ES ES06720706.8T patent/ES2476421T3/en active Active
- 2006-02-14 CA CA2598350A patent/CA2598350C/en not_active Expired - Fee Related
- 2006-02-17 AR ARP060100592A patent/AR053547A1/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1853222B1 (en) | 2014-05-28 |
| WO2006091417A1 (en) | 2006-08-31 |
| RU2007134576A (en) | 2009-03-27 |
| CA2598350A1 (en) | 2006-08-31 |
| ES2476421T3 (en) | 2014-07-14 |
| EP1853222A1 (en) | 2007-11-14 |
| AU2006216930A1 (en) | 2006-08-31 |
| AR053547A1 (en) | 2007-05-09 |
| US7704531B2 (en) | 2010-04-27 |
| AU2006216930B2 (en) | 2009-08-20 |
| BRPI0607766A2 (en) | 2010-03-23 |
| US20060204463A1 (en) | 2006-09-14 |
| PL1853222T3 (en) | 2015-02-27 |
| MX2007010017A (en) | 2007-10-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2598350C (en) | Enhanced efficacy aluminum or aluminum-zirconium antiperspirant salt compositions containing calcium salt(s) and betaine | |
| RU2214224C2 (en) | Antiperspirant and/or deodorizing stabilized aluminum-zirconium composition | |
| EP1653918B1 (en) | Enhanced efficacy antiperspirant compositions containing strontium or calcium | |
| JP2008501016A (en) | High pH antiperspirant composition with improved effect | |
| US6902724B1 (en) | Enhanced efficacy basic aluminum halides, antiperspirant active compositions and methods for making | |
| CA2629042A1 (en) | Antiperspirant compositions | |
| AU2001219520B2 (en) | Enhanced efficacy aluminum-zirconium antiperspirants and methods for making | |
| AU2003204505B2 (en) | Amino acid free stable aluminum/zirconium antiperspirant solution | |
| AU2001219520A1 (en) | Enhanced efficacy aluminum-zirconium antiperspirants and methods for making | |
| CA2534989A1 (en) | Stable aluminum/zirconium antiperspirant solution | |
| US20190365616A1 (en) | Activation And Stabilization Of Basic Aluminum Chloride Solution By Zinc | |
| AU624408B2 (en) | Basic aluminum antiperspirant active material having enhanced activity, antiperspirant active composition containing such material, and methods for preparation of such material and composition | |
| AU2004324474A1 (en) | Activated aluminum/depolymerized zirconium antiperspirant compositions | |
| MXPA00004127A (en) | Improved antiperspirant actives and formulations made therefrom |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20190214 |